WO2016179217A1 - Metal ion chelation for enhancing the effect of tissue plasminogen activator (tpa) in thromobolysis - Google Patents
Metal ion chelation for enhancing the effect of tissue plasminogen activator (tpa) in thromobolysis Download PDFInfo
- Publication number
- WO2016179217A1 WO2016179217A1 PCT/US2016/030663 US2016030663W WO2016179217A1 WO 2016179217 A1 WO2016179217 A1 WO 2016179217A1 US 2016030663 W US2016030663 W US 2016030663W WO 2016179217 A1 WO2016179217 A1 WO 2016179217A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tpa
- metal ion
- composition
- ion chelator
- thrombolytic drug
- Prior art date
Links
- 229910021645 metal ion Inorganic materials 0.000 title claims abstract description 105
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 title claims description 210
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 title claims description 210
- 229960000187 tissue plasminogen activator Drugs 0.000 title claims description 205
- 230000000694 effects Effects 0.000 title description 40
- 230000009920 chelation Effects 0.000 title description 24
- 230000002708 enhancing effect Effects 0.000 title description 2
- 239000002738 chelating agent Substances 0.000 claims abstract description 108
- 239000000203 mixture Substances 0.000 claims abstract description 86
- 239000003527 fibrinolytic agent Substances 0.000 claims abstract description 81
- 238000000034 method Methods 0.000 claims abstract description 42
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 214
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 172
- 239000011701 zinc Substances 0.000 claims description 116
- 229910052725 zinc Inorganic materials 0.000 claims description 111
- 229910052742 iron Inorganic materials 0.000 claims description 83
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 51
- 229960001484 edetic acid Drugs 0.000 claims description 48
- 108010023197 Streptokinase Proteins 0.000 claims description 34
- 229960005202 streptokinase Drugs 0.000 claims description 33
- 208000006011 Stroke Diseases 0.000 claims description 22
- -1 calcium saturated EDTA Chemical class 0.000 claims description 18
- 230000035602 clotting Effects 0.000 claims description 18
- 206010053567 Coagulopathies Diseases 0.000 claims description 15
- 239000011575 calcium Substances 0.000 claims description 13
- 229910052791 calcium Inorganic materials 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 4
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 4
- 229960002897 heparin Drugs 0.000 claims description 4
- 229920000669 heparin Polymers 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 3
- 102000007625 Hirudins Human genes 0.000 claims description 3
- 108010007267 Hirudins Proteins 0.000 claims description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 3
- 206010047249 Venous thrombosis Diseases 0.000 claims description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 3
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 3
- 229940001468 citrate Drugs 0.000 claims description 3
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 3
- 229960003009 clopidogrel Drugs 0.000 claims description 3
- 235000001671 coumarin Nutrition 0.000 claims description 3
- 150000004775 coumarins Chemical class 0.000 claims description 3
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 3
- 229940006607 hirudin Drugs 0.000 claims description 3
- 229940039748 oxalate Drugs 0.000 claims description 3
- 229960005080 warfarin Drugs 0.000 claims description 3
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims description 3
- 230000002537 thrombolytic effect Effects 0.000 description 128
- 208000007536 Thrombosis Diseases 0.000 description 48
- 238000011282 treatment Methods 0.000 description 40
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 39
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 36
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 35
- 230000009089 cytolysis Effects 0.000 description 26
- 238000002835 absorbance Methods 0.000 description 25
- 230000037396 body weight Effects 0.000 description 24
- 230000001965 increasing effect Effects 0.000 description 22
- 150000002500 ions Chemical class 0.000 description 22
- 210000001105 femoral artery Anatomy 0.000 description 20
- 230000008859 change Effects 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 230000010410 reperfusion Effects 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 108010054147 Hemoglobins Proteins 0.000 description 12
- 102000001554 Hemoglobins Human genes 0.000 description 12
- 230000005540 biological transmission Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 11
- 102000009123 Fibrin Human genes 0.000 description 10
- 108010073385 Fibrin Proteins 0.000 description 10
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 10
- 208000032843 Hemorrhage Diseases 0.000 description 10
- 229950003499 fibrin Drugs 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- CVRXLMUYFMERMJ-UHFFFAOYSA-N N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine Chemical compound C=1C=CC=NC=1CN(CC=1N=CC=CC=1)CCN(CC=1N=CC=CC=1)CC1=CC=CC=N1 CVRXLMUYFMERMJ-UHFFFAOYSA-N 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000000443 aerosol Substances 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 230000023555 blood coagulation Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000010412 perfusion Effects 0.000 description 8
- 239000013589 supplement Substances 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 210000001367 artery Anatomy 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 238000002798 spectrophotometry method Methods 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000015271 coagulation Effects 0.000 description 6
- 238000005345 coagulation Methods 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 239000003380 propellant Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 206010043647 Thrombotic Stroke Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 208000034158 bleeding Diseases 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 208000029028 brain injury Diseases 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- JYXGIOKAKDAARW-UHFFFAOYSA-N N-(2-hydroxyethyl)iminodiacetic acid Chemical compound OCCN(CC(O)=O)CC(O)=O JYXGIOKAKDAARW-UHFFFAOYSA-N 0.000 description 4
- 102000013566 Plasminogen Human genes 0.000 description 4
- 108010051456 Plasminogen Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- JLVSRWOIZZXQAD-UHFFFAOYSA-N 2,3-disulfanylpropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(S)CS JLVSRWOIZZXQAD-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 206010048962 Brain oedema Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000008857 Ferritin Human genes 0.000 description 3
- 108050000784 Ferritin Proteins 0.000 description 3
- 238000008416 Ferritin Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000032382 Ischaemic stroke Diseases 0.000 description 3
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 3
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
- 206010048259 Zinc deficiency Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229960003318 alteplase Drugs 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000006931 brain damage Effects 0.000 description 3
- 231100000874 brain damage Toxicity 0.000 description 3
- 208000006752 brain edema Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229960000958 deferoxamine Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003073 embolic effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- IFQUWYZCAGRUJN-UHFFFAOYSA-N ethylenediaminediacetic acid Chemical compound OC(=O)CNCCNCC(O)=O IFQUWYZCAGRUJN-UHFFFAOYSA-N 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 159000000014 iron salts Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000016273 neuron death Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- ACTRVOBWPAIOHC-UHFFFAOYSA-N succimer Chemical compound OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000011592 zinc chloride Substances 0.000 description 3
- 229940091251 zinc supplement Drugs 0.000 description 3
- URDCARMUOSMFFI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(2-hydroxyethyl)amino]acetic acid Chemical compound OCCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O URDCARMUOSMFFI-UHFFFAOYSA-N 0.000 description 2
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 2
- IWTIBPIVCKUAHK-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)amino]propanoic acid Chemical compound OC(=O)CCN(CCC(O)=O)CCC(O)=O IWTIBPIVCKUAHK-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 108010058207 Anistreplase Proteins 0.000 description 2
- 108010006591 Apoenzymes Proteins 0.000 description 2
- 108010026206 Conalbumin Proteins 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 206010014498 Embolic stroke Diseases 0.000 description 2
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 description 2
- 108010088842 Fibrinolysin Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 102000010750 Metalloproteins Human genes 0.000 description 2
- 108010063312 Metalloproteins Proteins 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 108010039185 Tenecteplase Proteins 0.000 description 2
- 229940099983 activase Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229940116901 diethyldithiocarbamate Drugs 0.000 description 2
- LMBWSYZSUOEYSN-UHFFFAOYSA-N diethyldithiocarbamic acid Chemical compound CCN(CC)C(S)=S LMBWSYZSUOEYSN-UHFFFAOYSA-N 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- PZZHMLOHNYWKIK-UHFFFAOYSA-N eddha Chemical compound C=1C=CC=C(O)C=1C(C(=O)O)NCCNC(C(O)=O)C1=CC=CC=C1O PZZHMLOHNYWKIK-UHFFFAOYSA-N 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- 229940093503 ethyl maltol Drugs 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 150000002505 iron Chemical class 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- HKRNYOZJJMFDBV-UHFFFAOYSA-N n-(6-methoxyquinolin-8-yl)-4-methylbenzenesulfonamide Chemical compound C=12N=CC=CC2=CC(OC)=CC=1NS(=O)(=O)C1=CC=C(C)C=C1 HKRNYOZJJMFDBV-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- VHQQPFLOGSTQPC-UHFFFAOYSA-N pentatriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC VHQQPFLOGSTQPC-UHFFFAOYSA-N 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108010051412 reteplase Proteins 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 201000005665 thrombophilia Diseases 0.000 description 2
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- 239000011746 zinc citrate Substances 0.000 description 2
- 235000006076 zinc citrate Nutrition 0.000 description 2
- 229940068475 zinc citrate Drugs 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- DDKJKQVNNATMAD-JEDNCBNOSA-N (2s)-2,6-diaminohexanoic acid;zinc Chemical class [Zn].NCCCC[C@H](N)C(O)=O DDKJKQVNNATMAD-JEDNCBNOSA-N 0.000 description 1
- WMTBUOGSWYCHRF-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;zinc Chemical compound [Zn].OC(=O)[C@@H](N)CC1=CNC=N1 WMTBUOGSWYCHRF-JEDNCBNOSA-N 0.000 description 1
- BWPMKVHHFNGYEN-CJAUYULYSA-N (4S,5R)-N-[4-[(2,3-dihydroxybenzoyl)amino]butyl]-N-[3-[(2,3-dihydroxybenzoyl)amino]propyl]-2-(2,3-dihydroxyphenyl)-5-methyl-4,5-dihydro-1,3-oxazole-4-carboxamide Chemical compound C[C@H]1OC(=N[C@@H]1C(=O)N(CCCCNC(=O)c1cccc(O)c1O)CCCNC(=O)c1cccc(O)c1O)c1cccc(O)c1O BWPMKVHHFNGYEN-CJAUYULYSA-N 0.000 description 1
- FRCJDPPXHQGEKS-BCHFMIIMSA-N (4S,5R)-N-[4-[(2,3-dihydroxybenzoyl)amino]butyl]-N-[3-[(2,3-dihydroxybenzoyl)amino]propyl]-2-(2-hydroxyphenyl)-5-methyl-4,5-dihydro-1,3-oxazole-4-carboxamide Chemical compound C[C@H]1OC(=N[C@@H]1C(=O)N(CCCCNC(=O)c1cccc(O)c1O)CCCNC(=O)c1cccc(O)c1O)c1ccccc1O FRCJDPPXHQGEKS-BCHFMIIMSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- PKMTWMDBJHRDBM-ODZAUARKSA-N (z)-but-2-enedioic acid;zinc Chemical compound [Zn].OC(=O)\C=C/C(O)=O PKMTWMDBJHRDBM-ODZAUARKSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QPDPTLJZZJWCEI-UHFFFAOYSA-N 2-(hydroxymethyl)-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(CO)C(=O)C1=CC=CC=C1 QPDPTLJZZJWCEI-UHFFFAOYSA-N 0.000 description 1
- XNCSCQSQSGDGES-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(O)=O XNCSCQSQSGDGES-UHFFFAOYSA-N 0.000 description 1
- GRUVVLWKPGIYEG-UHFFFAOYSA-N 2-[2-[carboxymethyl-[(2-hydroxyphenyl)methyl]amino]ethyl-[(2-hydroxyphenyl)methyl]amino]acetic acid Chemical compound C=1C=CC=C(O)C=1CN(CC(=O)O)CCN(CC(O)=O)CC1=CC=CC=C1O GRUVVLWKPGIYEG-UHFFFAOYSA-N 0.000 description 1
- RNMCCPMYXUKHAZ-UHFFFAOYSA-N 2-[3,3-diamino-1,2,2-tris(carboxymethyl)cyclohexyl]acetic acid Chemical compound NC1(N)CCCC(CC(O)=O)(CC(O)=O)C1(CC(O)=O)CC(O)=O RNMCCPMYXUKHAZ-UHFFFAOYSA-N 0.000 description 1
- FCKYPQBAHLOOJQ-UWVGGRQHSA-N 2-[[(1s,2s)-2-[bis(carboxymethyl)amino]cyclohexyl]-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)[C@H]1CCCC[C@@H]1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UWVGGRQHSA-N 0.000 description 1
- SPSVHTNOLQKTGV-UHFFFAOYSA-N 2-hydroxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(O)C(=O)C1=CC=CC=C1 SPSVHTNOLQKTGV-UHFFFAOYSA-N 0.000 description 1
- 125000006290 2-hydroxybenzyl group Chemical group [H]OC1=C(C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 description 1
- MFOAIOKYYWRALA-UHFFFAOYSA-N 4-[(6-methoxy-2-methylquinolin-8-yl)sulfamoyl]benzoic acid Chemical compound C=12N=C(C)C=CC2=CC(OC)=CC=1NS(=O)(=O)C1=CC=C(C(O)=O)C=C1 MFOAIOKYYWRALA-UHFFFAOYSA-N 0.000 description 1
- XIXFNVDWEWCEOI-UHFFFAOYSA-N 5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]quinolin-8-ol Chemical compound C1CN(CCO)CCN1CC1=CC=C(O)C2=NC=CC=C12 XIXFNVDWEWCEOI-UHFFFAOYSA-N 0.000 description 1
- 150000004325 8-hydroxyquinolines Chemical class 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010027612 Batroxobin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 239000004803 Di-2ethylhexylphthalate Substances 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108010061075 Enterobactin Proteins 0.000 description 1
- SERBHKJMVBATSJ-UHFFFAOYSA-N Enterobactin Natural products OC1=CC=CC(C(=O)NC2C(OCC(C(=O)OCC(C(=O)OC2)NC(=O)C=2C(=C(O)C=CC=2)O)NC(=O)C=2C(=C(O)C=CC=2)O)=O)=C1O SERBHKJMVBATSJ-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- KDHHWXGBNUCREU-HOTGVXAUSA-N Ferric-aerobactin Chemical compound CC(=O)N(O)CCCC[C@@H](C(O)=O)NC(=O)CC(O)(C(O)=O)CC(=O)N[C@H](C(O)=O)CCCCN(O)C(C)=O KDHHWXGBNUCREU-HOTGVXAUSA-N 0.000 description 1
- 108010067157 Ferrichrome Proteins 0.000 description 1
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101001057702 Haloferax volcanii (strain ATCC 29605 / DSM 3757 / JCM 8879 / NBRC 14742 / NCIMB 2012 / VKM B-1768 / DS2) Inorganic pyrophosphatase Proteins 0.000 description 1
- 101000582914 Homo sapiens Serine/threonine-protein kinase PLK4 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020608 Hypercoagulation Diseases 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- FRCJDPPXHQGEKS-UHFFFAOYSA-N Parabactin Natural products CC1OC(=NC1C(=O)N(CCCCNC(=O)c1cccc(O)c1O)CCCNC(=O)c1cccc(O)c1O)c1ccccc1O FRCJDPPXHQGEKS-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000000589 Siderophore Substances 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 240000007591 Tilia tomentosa Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- HMNDRWDQGZZYIC-UHFFFAOYSA-N [2-(phosphonomethylamino)ethylamino]methylphosphonic acid Chemical compound OP(O)(=O)CNCCNCP(O)(O)=O HMNDRWDQGZZYIC-UHFFFAOYSA-N 0.000 description 1
- XLIJUKVKOIMPKW-BTVCFUMJSA-N [O].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O Chemical compound [O].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XLIJUKVKOIMPKW-BTVCFUMJSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- ZMIMMNZVPRFQQM-UHFFFAOYSA-N acetic acid;2-aminophenol Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.NC1=CC=CC=C1O ZMIMMNZVPRFQQM-UHFFFAOYSA-N 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- BWPMKVHHFNGYEN-UHFFFAOYSA-N agrobactin Natural products CC1OC(=NC1C(=O)N(CCCCNC(=O)c1cccc(O)c1O)CCCNC(=O)c1cccc(O)c1O)c1cccc(O)c1O BWPMKVHHFNGYEN-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229960000983 anistreplase Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000005756 apoptotic signaling Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 229960002210 batroxobin Drugs 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- HJMZMZRCABDKKV-UHFFFAOYSA-N carbonocyanidic acid Chemical compound OC(=O)C#N HJMZMZRCABDKKV-UHFFFAOYSA-N 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- UGJSEILLHZKUBG-HNCPQSOCSA-M chembl63540 Chemical compound [Na+].[O-]C(=O)[C@@]1(C)CSC(C=2C(=CC=CN=2)O)=N1 UGJSEILLHZKUBG-HNCPQSOCSA-M 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960005228 clioquinol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 239000008294 cold cream Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 229960001489 deferasirox Drugs 0.000 description 1
- FMSOAWSKCWYLBB-VBGLAJCLSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N(N\C(N\1)=C\2C(C=CC=C/2)=O)C/1=C\1C(=O)C=CC=C/1 FMSOAWSKCWYLBB-VBGLAJCLSA-N 0.000 description 1
- 229960003266 deferiprone Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical compound C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
- 229960001051 dimercaprol Drugs 0.000 description 1
- QBEFIFWEOSUTKV-UHFFFAOYSA-N dimethylheptylpyran Chemical compound CC1(C)OC2=CC(C(C)C(C)CCCCC)=CC(O)=C2C2=C1CCC(C)C2 QBEFIFWEOSUTKV-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- SERBHKJMVBATSJ-BZSNNMDCSA-N enterobactin Chemical compound OC1=CC=CC(C(=O)N[C@@H]2C(OC[C@@H](C(=O)OC[C@@H](C(=O)OC2)NC(=O)C=2C(=C(O)C=CC=2)O)NC(=O)C=2C(=C(O)C=CC=2)O)=O)=C1O SERBHKJMVBATSJ-BZSNNMDCSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- GGUNGDGGXMHBMJ-UHFFFAOYSA-N ferrichrome Chemical compound [Fe+3].CC(=O)N([O-])CCCC1NC(=O)CNC(=O)CNC(=O)CNC(=O)C(CCCN([O-])C(C)=O)NC(=O)C(CCCN([O-])C(C)=O)NC1=O GGUNGDGGXMHBMJ-UHFFFAOYSA-N 0.000 description 1
- 108010020867 ferrioxamine E Proteins 0.000 description 1
- SRMBQCVUAVULDJ-UHFFFAOYSA-N ferrioxamine b Chemical compound [Fe+3].CC(=O)N([O-])CCCCCNC(=O)CCC(=O)N([O-])CCCCCNC(=O)CCC(=O)N([O-])CCCCCN SRMBQCVUAVULDJ-UHFFFAOYSA-N 0.000 description 1
- MZFKJKOHYACYNT-UHFFFAOYSA-N ferrioxamine e Chemical compound [Fe+3].[O-]N1CCCCCNC(=O)CCC(=O)N([O-])CCCCCNC(=O)CCC(=O)N([O-])CCCCCNC(=O)CCC1=O MZFKJKOHYACYNT-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 230000018127 platelet degranulation Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000009024 positive feedback mechanism Effects 0.000 description 1
- YNGNXRJCOYOGHQ-UHFFFAOYSA-M potassium;4-[(6-methoxy-2-methylquinolin-8-yl)sulfamoyl]benzoate Chemical compound [K+].C=12N=C(C)C=CC2=CC(OC)=CC=1NS(=O)(=O)C1=CC=C(C([O-])=O)C=C1 YNGNXRJCOYOGHQ-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 208000012802 recumbency Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229940116243 retavase Drugs 0.000 description 1
- 229960002917 reteplase Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960004533 streptodornase Drugs 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- ACTRVOBWPAIOHC-XIXRPRMCSA-N succimer Chemical compound OC(=O)[C@@H](S)[C@@H](S)C(O)=O ACTRVOBWPAIOHC-XIXRPRMCSA-N 0.000 description 1
- 229960005346 succimer Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960000216 tenecteplase Drugs 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940113038 tnkase Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- LLMKLMMXMOTPRU-YOAXHERRSA-N vibriobactin Chemical compound O=C([C@@H]1N=C(O[C@H]1C)C=1C(=C(O)C=CC=1)O)NCCCN(C(=O)[C@@H]1[C@H](OC(=N1)C=1C(=C(O)C=CC=1)O)C)CCCNC(=O)C1=CC=CC(O)=C1O LLMKLMMXMOTPRU-YOAXHERRSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229940056904 zinc ascorbate Drugs 0.000 description 1
- 229940062776 zinc aspartate Drugs 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 229940071566 zinc glycinate Drugs 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- 229940110280 zinc methionine Drugs 0.000 description 1
- 229940032991 zinc picolinate Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
- WWRJFSIRMWUMAE-ZZMNMWMASA-L zinc;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-olate Chemical compound [Zn+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] WWRJFSIRMWUMAE-ZZMNMWMASA-L 0.000 description 1
- BRKFIPNBXFDCDM-MDTVQASCSA-L zinc;(2s)-2-amino-3-(1h-imidazol-5-yl)propanoate Chemical compound [Zn+2].[O-]C(=O)[C@@H](N)CC1=CNC=N1.[O-]C(=O)[C@@H](N)CC1=CNC=N1 BRKFIPNBXFDCDM-MDTVQASCSA-L 0.000 description 1
- CNMFGFBWPBBGKX-SCGRZTRASA-L zinc;(2s)-2-amino-4-methylsulfanylbutanoate Chemical compound [Zn+2].CSCC[C@H](N)C([O-])=O.CSCC[C@H](N)C([O-])=O CNMFGFBWPBBGKX-SCGRZTRASA-L 0.000 description 1
- POEVDIARYKIEGF-CEOVSRFSSA-L zinc;(2s)-2-aminobutanedioate;hydron Chemical compound [Zn+2].[O-]C(=O)[C@@H](N)CC(O)=O.[O-]C(=O)[C@@H](N)CC(O)=O POEVDIARYKIEGF-CEOVSRFSSA-L 0.000 description 1
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 description 1
- AGFGXVAAIXIOFZ-UHFFFAOYSA-L zinc;butanedioate Chemical compound [Zn+2].[O-]C(=O)CCC([O-])=O AGFGXVAAIXIOFZ-UHFFFAOYSA-L 0.000 description 1
- WDHVIZKSFZNHJB-UHFFFAOYSA-L zinc;butanoate Chemical compound [Zn+2].CCCC([O-])=O.CCCC([O-])=O WDHVIZKSFZNHJB-UHFFFAOYSA-L 0.000 description 1
- XDWXRAYGALQIFG-UHFFFAOYSA-L zinc;propanoate Chemical compound [Zn+2].CCC([O-])=O.CCC([O-])=O XDWXRAYGALQIFG-UHFFFAOYSA-L 0.000 description 1
- NHVUUBRKFZWXRN-UHFFFAOYSA-L zinc;pyridine-2-carboxylate Chemical compound C=1C=CC=NC=1C(=O)O[Zn]OC(=O)C1=CC=CC=N1 NHVUUBRKFZWXRN-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A61K38/166—Streptokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- Ischemic stroke is the rapid loss of brain function because of the interruption of blood flow, and subsequently brain damage from oxygen-glucose deprivation due to thrombosis or embolism. Stroke is the second leading cause of death worldwide according to the World Health Organization, and the fifth leading cause of death in the US according to the Centers for Disease Control. Furthermore, it is a leading cause of serious long-term disability. Therefore, stroke has a significant impact and burden on individuals, the health care system, and society. Early and adequate medical intervention is critical for improving stroke outcomes. However, the only drug approved by FDA for treatment of acute thrombotic stroke so far is tissue plasminogen activator (tPA), referred to as the Gold Standard by the American Stroke Association.
- tPA tissue plasminogen activator
- a composition comprising an effective amount of a thrombolytic drug, at least one metal ion chelator capable of chelating zinc or iron, and a pharmaceutically acceptable excipient, diluent, or carrier.
- the thrombolytic drug comprises tissue plasminogen activator (tPA).
- the thrombolytic drug comprises streptokinase.
- the metal ion chelator is capable of chelating both zinc and iron.
- the metal ion chelator comprises ethylenediaminetetra-acetic acid (EDTA).
- the EDTA comprises calcium saturated EDTA (CaEDTA).
- the effective amount of the thrombolytic drug is less than an amount of the thrombolytic drug needed to be effective in the absence of the at least one metal ion chelator. In certain embodiments, the effective amount of the thrombolytic drug ranges from about 0.25 mg/kg to about 20 mg kg. In certain embodiments, the effective amount of the thrombolytic drug is about 2 mg kg. In certain embodiments, the effective amount of the thrombolytic drug is about 1 mg/kg. In certain embodiments, the effective amount of the thrombolytic drug is about 0.5 mg/kg. In certain embodiments, the at least one metal ion chelator is present at a concentration ranging from about 1 ⁇ to about 100 mM .
- the composition further includes a second metal ion chelator capable of chelating zinc or ion.
- the metal ion chelator comprises N,N,N',N'-tetrakis(2-pyrdiylmethyl) ethylenediamine (TPEN).
- the metal ion chelator comprises EDTA and TPEN.
- the composition further includes an additional agent selected from the group consisting of: aspirin, heparin, coumarins (such as warfarin), clopidogrel, oxalate, citrate, hirudin, and combinations thereof.
- a method of treating a clotting event comprising the steps of administering an effective amount of a metal ion chelator to a patient having a clotting event, and administering an effective amount of a thrombolytic drug to the patient to treat the clotting event.
- the thrombolytic drug comprises tissue plasminogen activator (tPA).
- tPA tissue plasminogen activator
- the metal ion chelator and the thrombolytic drug are administered simultaneously.
- the metal ion chelator and the thrombolytic drug are in a single composition.
- the metal ion chelator and the thrombolytic drug are administering sequentially.
- the clotting event is selected from the group consisting of: stroke, myocardial infarction, vein thrombosis, and pulmonary embolism.
- the clotting event is a stroke
- the thrombolytic drug is tPA.
- the effective amount of the tPA is about 0.5 mg/kg or higher.
- the metal ion chelator comprises EDTA.
- the metal ion chelator comprises calcium saturated EDTA (CaEDTA).
- the metal ion chelator comprises TPEN.
- the thrombolytic drug comprises
- the effective amount of streptokinase ranges from about 10,000 units to about 100,000,000 units.
- the metal ion chelator comprises EDTA and TPEN.
- kits for preparing a composition comprising a first container housing a thrombolytic drug, and a second container housing a metal ion chelator.
- the metal ion chelator comprises EDTA and the thrombolytic drug comprises tPA.
- the kit further includes a syringe.
- FIG. 1 Diagram of embolic or thrombotic stroke and stroke treatment with tPA.
- FIG. 2 Diagram of embolic or thrombotic stroke and stroke treatment with tPA versus with a composition having a metal ion chelator and one -half the otherwise required dosage of tPA.
- FIGS. 3A-3C The set-up for blood clot lysis (thrombolysis) in vitro spectrophotometric measurement.
- FIG. 3A shows a schematic diagram of the custom-modified cuvette used.
- FIG. 3B shows a photograph of the cuvettes at the start of thrombolysis. Each blood clot was formed from 200 recalcified CDl mouse blood, and transferred into the cuvette. The color of lystate at this point was clear, and the absorbance was low.
- FIG. 3C shows a photograph of the cuvettes after 60 minutes of thrombolysis. Cuvette 1, 2, and 3 represented lysate of three doses of tPA (0.005 mg, 0.01 mg, and 0.05 mg).
- FIGS. 4A-4D The clot-lysis represented by absorbance at 1 hour in different
- FIG. 4A shows the thrombolysis curve of tPA.
- FIG. 4B shows quantified thrombolysis at one hour treatment with tPA and tPA plus different metal ions. The dose of tPA was 0.01 mg. ZnCl 2 : 200 ⁇ . FeC , FeC : 100 ⁇ .
- FIG. 4C shows the rate of thrombolysis of tPA.
- FIG. 4D shows the maximum rate of thrombolysis of tPA and tPA plus metal ions. Saline was used as a vehicle in these treatments. Data were shown as mean + SEM.
- FIGS. 7A-7B Effect of EDTA on clot-lysis of tPA. Ion chelation promotes tPA-induced thrombolysis. These graphs show the effect of EDTA on tPA-induced thrombolysis in 60 minutes.
- FIG. 7A shows quantified thrombolysis represented by change of optical density in 60 minutes.
- FIGS. 8A-8C Clot-lysis in vivo.
- FIG. 8A shows the exposure of the femoral artery on the CD1 mouse. The arrow shows the femoral artery. Scale bar: 1 cm.
- FIG. 8B shows photo thrombosis formed in the femoral artery (shown as the arrow), leaving the downstream blood-free (outlined by dash lines).
- FIG. 8C shows thrombolysis after tPA perfusion. Scale bar: 1 mm
- FIGS. 9A-9B Ion chelation improves reperfusion outcomes after photothrombosis of artery. These figures show real-time thrombolysis in vivo.
- FIG. 9A shows thrombolysis at each time point (0, 10, 20, 30, and 40 min), with different tPA treatments (tPA, 1 ⁇ 2 tPA and 1 ⁇ 2 tPA + CaEDTA). Femoral arteries were outlined by dash lines. Scale bar, 0.5mm.
- FIG. 9B shows the change of light transmission in each thrombosis. Empty dots represent data from reperfused cases. Black square dots represent data from non-reperfused cases. P ⁇ 0.01 between those two groups.
- FIG. 12 Graph showing the percentage of blood clot lysis from different treatments.
- the metal ion chelator CaEDTA or TPEN increased clot lysis when co-applied with streptokinase (SK), compared to lysis of the control groups (SK, CaEDTA, or TPEN alone).
- the addition of chelator without SK showed little to no lysis.
- FIG. 13 Graph showing the blood clot lysis from different treatments. The addition of zinc (200 ⁇ ) inhibited the streptokinase (SK)-induced clot lysis when compared to the lysis of the streptokinase treatment group.
- tPA is the only drug approved by the FDA for treatment of acute thrombotic stroke, and the standard of care for treatment of acute thrombotic stroke, it must be administered as early as possible after the onset of stroke symptoms in order to be effective in the treatment of ischemic stroke. Protocol guidelines require its use intravenously within the first three hours of the event, after which its detrimental side effects may outweigh its benefits. Therefore, the patient needs to present in the hospital soon after the onset of stroke symptoms, which is almost impossible. For this reason, only about 1-3% of stroke patients in the United States receive this therapy.
- the bloodstream contains and transports a large variety of ions, including major trace elements zinc and iron.
- the dyshomeostasis of these metal ions is closely correlated to the pathogenesis of cerebral ischaemia, contributing significantly to brain damage in stroke.
- Zinc (Zn 2+ ) has been correlated to cell damage in stroke. Without wishing to be bound by theory, it is believed that both zinc and iron are involved in the clotting of blood. Iron is important for red blood cells and plays role in coagulation. Similarly, zinc deficiency can lead to increased bleeding tendency and delayed wound healing by poor platelet aggregation.
- the concentration of total zinc in blood plasma is around 15 ⁇ or 60-120 ⁇ g /100ml, which is bound predominantly to blood proteins.
- a substantial amount of zinc has also been found in various cellular compartments, vesicles, or vacuoles.
- Zn is stored in many types of cells, including platelets, which are responsible for making clots. Zn concentration is high (in the micromolar range) in platelets.
- the most zinc-enriched site is the a-granule of platelets, where the zinc concentration reaches 500 ⁇ . This is almost a 30-fold higher level of zinc in platelets than in the serum.
- iron also has intracellular and extracellular repositories.
- the amount of serum iron is 60-170 ⁇ g /100ml, which is slightly higher than serum zinc.
- the hemoglobin of erythrocytes is the major site of iron storage. About 65% of the iron in the body is bound up in hemoglobin, where iron is bound with heme. Iron is strictly regulated by the binding of proteins such as transferrin in the bloodstream and ferritin in cell plasma.
- the platelets and erythrocytes are physiologically important for thrombus formation.
- a large amount of zinc releases from platelets and leads to a surge in zinc concentrations in the local microenvironment of an expanding thrombus, which promotes fibrin formation and triggers key signalling events that lead to platelet aggregation.
- aggregated platelets and erythrocytes are major components in thrombus composition.
- platelets and erythrocytes store a substantial amount of zinc (in platelet granules) and iron (in hemes), thrombi become a source of these metal ions as they are "trapped" in the thrombi.
- the precise role of these thrombus ions is not known. However, without wishing to be bound by theory, it believed that zinc enhances the production of fibrin, and free iron promotes blood coagulation and increases fibrinogen strength. Hence, the presence of increasing free zinc and iron creates resistance to thrombolysis.
- Zinc is part of the processes of thrombosis and thrombolysis, and is involved in several steps of blood coagulation. For example, zinc triggers platelets aggregation. High concentrated zinc is packed in a-granules of platelets, which make platelets the highest zinc-containing cells among hematocytes. Zinc can affect hemostasis by directly affecting the function of platelets. The activated platelets secrete the contents of these granules through platelet exocytosis. During coagulation and thrombosis, the platelets undergo the cascade of activation, adhesion, and aggregation as the important part of the clot formation process.
- Zinc has been shown to induce platelet aggregation and affect ADP-induced aggregation in a synergistic manner. Zinc deficient rodents and humans have all displayed an increase in bleeding time and a decrease in platelet function. Zinc interacts with factor FXII and may be an essential cofactor. When local zinc concentration is 10-30 fold higher than plasma, zinc activates FXII and potentiates blood clotting. Zinc has been shown to regulate fibrinolytic pathways and to enhance the production of fibrin. When it comes to intensifying polymerization of fibrin oligomer, zinc is an introducer stronger than calcium. Furthermore, zinc prevents thrombolysis by inhibiting fibrin clearance. The presence of a substantial amount of zinc provides a positive feedback mechanism for platelet aggregation, the propagation of coagulation, and stabilizing the blood clot.
- iron Another ion that is important for thrombolysis is iron.
- an adult human contains 3-4 grams of iron with 2-3 grams in erythrocytes.
- Iron is also strictly regulated by the binding of proteins such as transferring in the bloodstream and ferritin in cell plasma. Free iron promotes blood coagulation.
- proteins such as transferring in the bloodstream and ferritin in cell plasma.
- Free iron promotes blood coagulation.
- iron also has intracellular and extracellular repositories, which are able to yield a locally high level of free Fe 3+ /Fe 2+ during thrombolysis.
- Platelets collapse during clot formation, creating a significant amount of Zn in the clot.
- Zn zinc and iron are dissociated from the blood clot, creating a focal high concentration of these ions.
- a thrombolytic drug such as tPA
- dissolves the clot the dissolution of the clot releases the Zn from the clot.
- this released Zn interacts with the thrombolytic drug.
- a high concentration of Fe is present in blood clots, such that when a thrombolytic drug dissolves a blood clot, the dissolution of the clot releases Fe from the clot. Without wishing to be bound by theory, it is believed that this released Fe interacts with the thrombolytic drug. More generally, it is believed that there are interactions between ions, such as zinc and iron, and thrombolysis mediated by a thrombolytic drug such as tPA.
- the zinc increase triggers platelets' activation and blood coagulation.
- the examples herein describe the effect of zinc and iron on the tPA-induced thrombolysis of a whole blood clot measured in vitro, which is a physiologically relevant model. The results show that the application of zinc or iron significantly inhibits tPA-induced thrombolysis. The therapeutic effect of metal ion chelation on tPA-induced thrombolysis in vivo was also evaluated. As seen from the examples, because zinc and iron inhibit tPA-induced thrombolysis, the chelation of these ions enhance its action. Removing zinc, removing iron, or removing both zinc and iron, with metal ion chelators accelerates tPA-mediated thrombolysis.
- Removing zinc, removing iron, or removing both zinc and iron, with metal ion chelators also reduces the necessary dose of tPA.
- the chelation removes not only chelatable ions in the serum but also free zinc and iron dissociated from the blood clots where tPA is inducing thrombolysis.
- the co- application of a metal ion chelator facilitates the action of tPA on the thrombolysis of a femoral artery thrombus.
- the chelation accelerates the rate of tPA-induced thrombolysis, enhances overall tPA-induced thrombolysis, and reduces tPA doses necessary for effective thrombolysis.
- compositions and methods that utilize the co-application of a chelator and a thrombolytic drug (such as tPA) to improve the efficacy, potency, and safety of the thrombolytic drug in the treatment of a clotting event such as a stroke.
- a thrombolytic drug such as tPA
- compositions that include a
- the thrombolytic drug and at least one metal ion chelator can enhance the potency and efficacy of the thrombolytic drug, and can reduce the necessary concentration of the thrombolytic drug.
- the composition can have the same efficacy as a certain concentration of the thrombolytic drug alone when it contains one-half the concentration of the thrombolytic drug in combination with a metal ion chelator.
- Both zinc and iron inhibit tPA-induced thrombolysis by postponing the maximum effect or decreasing tPA efficacy.
- the examples herein show further that the removal of zinc and/or iron, by the co-application of a metal ion chelator with a thrombolytic drug, enhances the effect of the thrombolytic drug-induced thrombolysis in vivo.
- tPA is described for exemplary purposes, it is to be understood that the present disclosure is not limited to tPA, and is not limited to applications involving clotting events in the brain.
- a metal ion chelator may be combined and/or co-applied with any other thrombolytic drugs to improve their potency and efficacy in treating, for example, myocardial infarction, vein thrombosis, or pulmonary embolism.
- the examples herein include an evaluation of a metal ion chelator with streptokinase.
- Streptokinase is a thrombolytic drug used for treating myocardial infarction and pulmonary embolism.
- co-application of a metal ion chelator was able to increase clot lysis caused by streptokinase (FIG. 12) as well as tPA
- compositions and methods herein can include any thrombolytic drugs (or combinations thereof), and are not limited to the treatment of strokes.
- Suitable thrombolytic drugs include, but are not limited to: tPA, streptokinase (Kabiknase, Streptase) or recombinant streptokinase, reteplase (Retavase), tenecteplase (TNKase), anistreplase (Eminase), urokinase (Abbokinase), single-chain urokinase-type plasminogen activator, plasminogen acetylation- streptokinase activate complex,reteplase, PPA, Batroxobin, Sak, venom thrombolytic enzymes, or combinations thereof. Further, it is understood that reference to "tissue plasminogen activator” and "tPA" and "tPA"
- the thrombolytic drug can be present in the composition at a concentration lower than would be necessary for effective thrombolysis in the absence of a metal ion chelator.
- concentration of the thrombolytic drug in the compositions ranging from about 0.1 mg kg to about 30 mg/kg, or from about 0.25 mg/kg to about 20 mg/kg.
- the thrombolytic drug is present at a concentration of only about 0.5 mg/kg or higher.
- the thrombolytic drug is present at a concentration of about 10 mg/kg.
- the effective amount of the streptokinase present in the composition may be expressed as units or international units.
- a "unit” refers to an amount of streptokinase which will liquefy a standard clot of fibrinogen, plasminogen, and thrombin at pH 7.5 at 37 °C in 10 minutes.
- An "international unit” of streptokinase is defined as the activity contained in 0.002090 mg of the international standard for streptokinase-streptodornase.
- the effective amount of streptokinase in accordance with the present disclosure can range from about 10,000 units to about 100,000,000 units.
- the metal ion chelator can be a chelator capable of chelating zinc (a "zinc chelator"), a chelator capable of chelating iron (an “iron chelator”), or a chelator capable of chelating both zinc and iron.
- the composition includes multiple metal ion chelators.
- the multiple metal ion chelators can each be zinc chelators, iron chelators, or combinations thereof.
- Suitable zinc chelators include, but are not limited to: ethylenediaminetetra-acetic acid (EDTA); l,3-diaminopropane-N,N,N',N'-tetraacetic acid (DTP A); N,N,N',N'-tetrakis(2- pyrdiylmethyl) ethylenediamine (TPEN); 1,10-phenanthroline; clioquinol; diethyldithiocarbamate (DEDTC), 2,3-dimercapto-l-propanesulfonic acid (DMPS); ethylenediamine-N,N'-diacetic-N,N'- di-B-propionic acid (EDPA); l,2-dimethyl-3-hydroxy-4-pyridinone (DMHP); l,2-diethyl-3- hydroxy-4-pyridinone (DEHP); ethylmaltol (EM), 4-(6-methoxy-8-quinaldinyl
- APTRA ethylenediarninetetra(methylenephosplioriic) acid
- EDTPO ethylenediarninetetra(methylenephosplioriic) acid
- HBED N,N'-bis(2- hydroxybenzyl)ethylenediamine-N,N'-diacetic acid
- HDTA hexamethylene-1,6- diaminetetraacetic acid
- HIDA hydroxyethyliminodiacetic acid
- IDA iminodiacetic acid
- NTA nitrilotriacetic acid
- NTP nitrilotripropionic acid
- NTPO nitrilotrimethylenphosphonic acid
- O-Bistren triethylenetetraaminehexaacetic acid
- TTHA triethylenetetraaminehexaacetic acid
- EGTA ethyleneglycol bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid
- BAPTA dimercaptosuccinic acid
- DMSA dimercaptosuccinic acid
- deferoxamine dimercaprol
- zinc citrate combinations of bismuth and citrate
- penicilamine penicilamine
- the zinc chelator is a wild-type apoenzyme or genetically engineered mutant thereof.
- the apoenzyme include, but are not limited to, apo-carbonic anhydrase, a S166C mutant, a H36C mutant, or a E117A mutant.
- Suitable iron chelators include, but are not limited to: ethylenediaminetetraacetic acid (EDTA); nitriloacetic acid; diethylenetriaminepentaacetic acid; ⁇ , ⁇ '-bis (2-hydroxybenzyl) ethylenediamine-N,N'-diacetic acid (HBED); dimercaptosuccinic acid; 2,3-dimercato-l- propanesulfonic acid (DMPS); alpha lipoic acid (ALA); 8 -hydroxy quinoline derivatives, such as 5- [4-(2-hydroxyethyl)piperazin-l-ylmethyl]-8-hydroxyquinoline; hydro xypyridinones, such as deferiprone; hydroxamates, such as desferrioxamine (DFO); amine carboxylates; catechols;
- EDTA ethylenediaminetetraacetic acid
- HBED diethylenetriaminepentaacetic acid
- HBED ⁇ , ⁇ '-bis (2-
- hydroxpyridinones pyridoxal isonicotinoly hydrazone (PIH) and derivatives thereof; siderophores, such as enterobactin, parabactin, agrobactin, fluviabactin, vulnibactin, vibriobactin, ferrioxamine B, ferrioxamine E, aerobactin, ferrichrome, and desferrithiocin and its analogues and derivatives; diketones, such as dibenzoylmethane (l,3-dephenyl-l,3-propanedione); beta-diketones, such as hydroxydibenzoyl methane or hydroxymethyldibenzoylmethane; salts thereof; and combinations thereof.
- siderophores such as enterobactin, parabactin, agrobactin, fluviabactin, vulnibactin, vibriobactin, ferrioxamine B, ferri
- the metal ion chelator is EDTA or a salt thereof, such as
- EDTA is a cell-impermeable metal ion chelator that has extremely high affinity to zinc and iron compared to other biologically relevant ions. Thus, EDTA is both a zinc chelator and an iron chelator.
- the EDTA stability constants of Zn 2+ , Fe 2+ , and Fe 3+ are 16.5, 14.3, and 25.1, respectively.
- CaEDTA is particularly useful as the metal ion chelator for several reasons. For instance, CaEDTA is more specific for zinc than other ions, such as calcium. Also, CaEDTA is an extracellular, membrane-impermeable chelator, meaning it generally does not cross the cellular membrane and remain inside cells.
- the metal ion chelator can be present in the composition at a concentration ranging from about 1 ⁇ to about 500 mM, or from about 10 ⁇ to about 100 mM.
- the metal ion chelator is typically present in the composition at a concentration ranging from about 1 mM to about 20 mM.
- the concentration of the metal ion chelator can be about 5 mM.
- the concentration of the metal ion chelator in the composition ranges from about 10 ⁇ to about 1000 ⁇ .
- the concentration of the metal ion chelator can be selected based on the desired use.
- the optimal concentration of metal ion chelator present in a composition with tPA, to be used to treat a stroke may be different from the optimal concentration of metal ion chelator present in a composition with streptokinase, to be used to treat myocardial infarction.
- the metal ion chelator can increase the efficacy and potency of tPA-mediated thrombolysis, and can expand the time window allotted for tPA treatment without the risk of its side effects.
- Zinc metalloproteins include transcription factors containing zinc fingers, structural proteins, and enzymes from all six enzyme classes. Zinc metalloproteins are present in virtually every cellular organelle of every cell type in the brain and body. Zinc is also important for DNA stabilization and gene expression. Thus, zinc deficiency can be harmful, or even fatal in some situations. Zinc deficiency can lead to increased bleeding tendency. Without wishing to be bound by theory, it is believed that chelating zinc to too low a level can induce seizures or facilitate apoptosis.
- compositions and methods herein should be practiced with an understanding of, and respect for, the importance of zinc in the overall body.
- iron is essential for red blood cells, and plays a role in coagulation. Iron deficiency is the most common cause of anemia. Iron deficiency may also cause reduced immunity. Accordingly, certain embodiments of the methods herein involve either monitoring free zinc and/or iron levels in a subject undergoing the treatment, and/or supplementing zinc and/or iron levels during or following the treatment.
- Zintrodes are chemical sensors/probes based on optical fibers which can be used to transmit excitation light from an illumination source to an analyte captured within an area of the probe, and to collect the return signal, either emission or scattering, onto a detector.
- the fiber optic probe is small and enables in vitro or in vivo real-time monitoring of biological fluids and in vivo implantation.
- the zintrode body is made of an inert, biocompatible material, such as a fluorocarbon, with a port or an area in the wall that is fitted with a material permeable to the analyte (Zn 2+ ), which reacts with a reagent contained within the body of the sensor.
- analyte Zn 2+
- serum iron levels can be monitored through a standard blood test.
- zinc levels can be supplemented through the
- Zinc supplements include, but are not limited to, one or more forms of inorganic or organic zinc, or combinations thereof, for oral or parenteral administration, including solid, gel, liposomal, and liquid forms.
- Non-limiting examples include zinc chloride (ZnC ); tetrabasic zinc chloride (ZnsCkfOEOs); zinc oxide (ZnO); zinc sulfate (ZnS04); zinc proteinates; zinc chelates; zinc amino acid complexes, such as zinc histidine, zinc methionine, or zinc lysine complexes; zinc acetate; zinc ascorbate; zinc aspartate; zinc butyrate; zinc carbonate; zinc citrate; zinc gluconate; zinc glycinate; zinc histidinate; zinc lactate; zinc maleate; zinc picolinate; zinc propanoate; zinc stearate; and zinc succinate.
- the zinc supplements are administered to deliver from about 10 mg to about 400 mg of elemental zinc per day for
- iron levels can be supplemented through the administration of any suitable iron supplement.
- Commonly available iron supplements generally include a single form of iron.
- iron supplements are available commercially in rapid release dosage forms and in controlled release dosage forms. Rapid release iron supplement dosage forms typically contain a "rapidly dissolving" iron salt. Certain iron salts are significantly more soluble in water and gastrointestinal fluids than other salts and metallic forms of iron. Hence, these more soluble iron salts or "rapidly dissolving" iron salts are incorporated into rapid release iron supplement dosage forms.
- the iron supplements are administered to deliver from about 1 mg to about 45 mg of iron per day for a desired period of time.
- consuming meat and fish can help supplement iron levels, as meat and fish generally contain a significant amount of heme iron, which is readily absorbed by humans.
- Zinc chelation has been shown to be neuroprotective in cellular and animal models.
- Subarachnoid hemorrhage (SAH) causes excess quantities of hemoglobin and its degradation production product, iron, in the perivascular space.
- SAH Subarachnoid hemorrhage
- Treatment with an iron chelator has been proven to reduce brain edema, cerebralvasospasm, and neuronal cell death in a rat model of SAH.
- the effective zinc and iron chelation facilitates tPA-induced thrombolysis and reduces the necessary dose of tPA treatment.
- a smaller dose of the thrombolytic drug (such as 50% than an otherwise effective dose) is needed to achieve a higher rate of reperfusion.
- the co- application of a thrombolytic drug and a metal ion chelator (within the same or a separate, co- applied composition) can reduce the adverse effects of tPA, such as hemorrhage.
- This co- application can also offer additional benefits.
- the presence of the metal ion chelator may remove zinc or iron accumulated inside of cells caused by hypoxic stress. Accumulated free iron injures endothelial cells by the production of free radicals.
- the presence of the metal ion chelator can improve neuronal survival by reducing the secondary brain injury or reperfusion brain injury.
- having a metal ion chelator can reduce the brain damage caused by hemorrhage. Therefore, metal ion chelation can also improve the outcome of thrombolysis by further reducing the adverse effect of a thrombolytic drug such as tPA, as well as the toxicities associated with dissociated zinc and iron.
- tPA thrombolytic drug
- a pharmaceutical composition as described herein may be formulated with any
- a composition disclosed herein may comprise different types of carriers depending on whether it is to be administered in solid, liquid, or aerosol form, and whether it needs to be sterile for such routes of administration as injection.
- compositions disclosed herein can be administered intravenously, intradermally, transdermally, intrathecally, intraarterially, intraperitoneally, intranasally, intravaginally, intrarectally, intraosseously, periprosthetically, topically (i.e., transdermal), intramuscularly, subcutaneously, mucosally (i.e., intranasally, vaginal, etc.), in utero, orally, topically, locally, via inhalation (e.g., aerosol inhalation), by injection, by infusion, by continuous infusion, by localized perfusion bathing target cells directly, via a catheter, via a lavage, in cremes, in lipid compositions (e.g., liposomes), parenterally (i.e., routes that bypass the alimentary tract, such as by injection or by continuous or discontinuous intra- arterial infusion), compressed into tablets or formulated as elixirs or solutions for convenient oral administration or administration by intramuscular or intravenous routes,
- compositions provided herein are useful for treating animals, such as humans, for various embolic or thrombotic conditions and clotting events.
- a method of treating a human patient according to the present disclosure includes the administration of an effective amount of a thrombolytic drug and a metal ion chelator, or pharmaceutical composition comprising the combination of a thrombolytic drug and a metal ion chelator.
- multiple pharmaceutical compositions - a first composition including a thrombolytic drug, and a second composition including a metal ion chelator - are administered.
- the metal ion chelator and thrombolytic drug can be administered sequentially or simultaneously.
- the metal ion chelator and thrombolytic drug are administered sequentially, there can be a delay of a desired period of time between the first administration and the second administration. Similarly, multiple cycles of sequential administration can be practiced, with or without a significant time delay between cycles.
- the thrombolytic drug and metal ion chelator can be in the form of, for example, tablets, lozenges, sublingual tablets, sachets, cachets, elixirs, gels, suspensions, aerosols, ointments, for example, containing from 1 to 10% by weight of the active compound in a suitable base, soft and hard gelatin capsules, suppositories, injectable solutions, and suspensions in physiologically acceptable media, or sterile packaged powders adsorbed onto a support material for making injectable solutions.
- the formulations useful for separate administration of the thrombolytic drug and metal ion chelator normally contain at least one compound selected from thrombolytic drugs and metal ion chelators (which may, individually or together, be referred to herein as the active ingredient or active substance) mixed with a pharmaceutically acceptable carrier, or diluted by a carrier, or enclosed or encapsulated by an ingestible carrier in the form of a capsule, sachet, cachet, paper, or other container, or by a disposable container such as an ampoule.
- pharmaceutically acceptable carrier or diluted by a carrier, or enclosed or encapsulated by an ingestible carrier in the form of a capsule, sachet, cachet, paper, or other container, or by a disposable container such as an ampoule.
- pharmaceutically acceptable carrier or diluted by a carrier, or enclosed or encapsulated by an ingestible carrier in the form of a capsule, sachet, cachet, paper, or other container, or by a disposable container such as an amp
- a carrier or diluent may be a solid, semi-solid, or liquid material which serves as a vehicle, excipient, or medium for the active therapeutic substance.
- Some examples of the diluents or carriers which may be employed in the pharmaceutical compositions of the present disclosure are lactose, dextrose, sucrose, sorbitol, mannitol, propylene glycol, liquid paraffin, white soft paraffin, kaolin, fumed silicon dioxide, microcrystalline cellulose, calcium silicate, silica, polyvinylpyrrolidone, cetostearyl alcohol, starch, modified starches, gum acacia, calcium phosphate, cocoa butter, ethoxylated esters, oil of theobroma, arachis oil, alginates, tragacanth, gelatin, syrup, methyl cellulose, polyoxyethylene sorbitan monolaurate, ethyl lactate, methyl and propyl hydro xybenzoate, sorbitan trioleate,
- a lubricant may be incorporated to prevent sticking and binding of the powdered ingredients in the dies and on the punch of the tableting machine.
- a lubricant may be employed, for instance, aluminum, magnesium, or calcium stearates, talc, or mineral oil.
- a composition and/or additional agent is formulated to be administered via an alimentary route.
- Alimentary routes include all possible routes of administration in which the composition is in direct contact with the alimentary tract.
- the pharmaceutical compositions disclosed herein may be administered orally, buccally, rectally, or sublingually.
- these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard- or soft- shell gelatin capsules, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.
- Solutions of the compositions disclosed herein as free bases or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as
- Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof, and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In certain cases the form should be sterile and should be fluid to the extent that easy injectability exists. It should be stable under the conditions of manufacture and storage and may optionally be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, a polyol (i.e., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils.
- a polyol i.e., glycerol, propylene glycol, and liquid polyethylene glycol, and the like
- suitable mixtures thereof and/or vegetable oils.
- vegetable oils i.e., glycerol, propylene glycol, and liquid polyethylene glycol, and the like
- Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion, and/or by the use of surfactants.
- the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, th
- isotonic agents such as, but not limited to, sugars or sodium chloride.
- Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption such as, for example, aluminum monostearate, or gelatin.
- the solution should be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose.
- aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration.
- Sterile aqueous media that can be employed will be known to those of skill in the art in light of the present disclosure.
- one dosage may be dissolved in 1 mL of isotonic NaCl solution and either added to 1000 mL of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences” 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
- Sterile injectable solutions are prepared by incorporating the compositions in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized compositions into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- some methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- a powdered composition is combined with a liquid carrier such as, e.g., water or a saline solution, with or without a stabilizing agent.
- compositions for topical administration may include the compositions formulated for a medicated application such as an ointment, paste, cream, or powder.
- Ointments include all oleaginous, adsorption, emulsion, and water-soluble based compositions for topical application, while creams and lotions are those compositions that include an emulsion base only.
- Topically administered medications may contain a penetration enhancer to facilitate adsorption of the active ingredients through the skin. Suitable penetration enhancers include glycerin, alcohols, alkyl methyl sulfoxides, pyrrolidones and luarocapram.
- compositions for topical application include polyethylene glycol, lanolin, cold cream, and petrolatum as well as any other suitable absorption, emulsion, or water-soluble ointment base.
- Topical preparations may also include emulsifiers, gelling agents, and antimicrobial preservatives as necessary to preserve the composition and provide for a homogenous mixture.
- Transdermal administration of the compositions may also comprise the use of a "patch.”
- the patch may supply one or more compositions at a predetermined rate and in a continuous manner over a fixed period of time.
- the compositions are suitable for delivery by eye drops, intranasal sprays, inhalation, and/or other aerosol delivery vehicles.
- Methods for delivering compositions directly to the lungs via nasal aerosol sprays have been described in U.S. Patents 5,756,353 and 5,804,212 (each specifically incorporated herein by reference in their entirety).
- the delivery of drugs using intranasal microparticle resins (Takenaga et al., 1998) and lysophosphatidyl-glycerol compounds (U.S. Patent 5,725, 871, specifically incorporated herein by reference in its entirety) are also well-known in the pharmaceutical arts and could be employed to deliver the compositions described herein.
- transmucosal drug delivery in the form of a polytetrafluoroetheylene support matrix is described in U.S. Patent 5,780,045 (specifically incorporated herein by reference in its entirety), and could be employed to deliver the
- compositions disclosed herein may be delivered via an aerosol.
- aerosol refers to a colloidal system of finely divided solid or liquid particles dispersed in a liquefied or pressurized gas propellant.
- the typical aerosol for inhalation consists of a suspension of active ingredients in liquid propellant or a mixture of liquid propellant and a suitable solvent.
- Suitable propellants include hydrocarbons and hydrocarbon ethers.
- Suitable containers will vary according to the pressure requirements of the propellant.
- Administration of the aerosol will vary according to subject's age, weight, and the severity and response of the symptoms.
- the actual dosage amount of a composition disclosed herein administered to an animal or human patient can be determined by physical and physiological factors such as body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, idiopathy of the patient, and the route of administration. Depending upon the dosage and the route of administration, the number of administrations of a preferred dosage and/or an effective amount may vary according to the response of the subject.
- the compounds of the present disclosure are generally effective over a wide dosage range. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject.
- compositions may comprise, for example, at least about 0.1% of an active compound.
- an active compound may comprise between about 2% to about 75% of the weight of the unit, or between about 25% to about 60%, for example, and any range derivable therein.
- the amount of active compound(s) in each therapeutically useful composition may be prepared in such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by those preparing such
- a dose may also comprise from about 1
- microgram kg/body weight about 5 micro gram/kg/body weight, about 10 microgram kg/body weight, about 50 microgram kg/body weight, about 100 microgram/kg/body weight, about 200 microgram/kg/body weight, about 350 microgram/kg/body weight, about 500 microgram/kg/body weight, about 1 milligram/kg/body weight, about 5 milligram/kg/body weight, about 10 milligram/kg/body weight, about 50 milligram/kg/body weight, about 100 milligram/kg/body weight, about 200 milligram/kg/body weight, about 350 milligram/kg/body weight, about 500 milligram/kg/body weight, to about 1000 mg/kg/body weight or more per administration, and any range derivable therein.
- a range of about 5 mg/kg/body weight to about 100 mg/kg/body weight, about 5 microgram/kg/body weight to about 500 milligram/kg/body weight, etc. can be administered, based on the numbers described above.
- the dosages will depend on many factors, and will in any event be determined by a suitable practitioner. Therefore, the dosages described herein are not intended to be limiting.
- compositions further include an additional active ingredient, in addition to the thrombolytic drug and metal ion chelator.
- additional active ingredient in addition to the thrombolytic drug and metal ion chelator.
- the preparation of a pharmaceutical composition that contains at least one compound or additional active ingredient will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington' s
- compositions of the present disclosure comprise an effective amount of a thrombolytic drug and an effective amount of a metal ion chelator, and/or additional agents, dissolved or dispersed in a pharmaceutically acceptable carrier.
- additional agents include, but are not limited to, anti-coagulants or blood thinners.
- the composition includes an additional agent selected from the group consisting of: aspirin, heparin, coumarins (such as warfarin), clopidogrel, oxalate, citrate, hirudin, and combinations thereof.
- kits A non-limiting example of such a kit comprises the ingredients for preparing a composition, namely a thrombolytic drug and a metal ion chelator, in separate (or at least two or more) containers, where the containers may or may not be present in a combined configuration. Many other kits are possible, such as kits comprising a second metal ion chelator or pharmaceutically acceptable additive in a separate container.
- the kits further comprise a means for administering the composition, such as a syringe.
- the kits may further include instructions for using the components of the kit to practice the subject methods.
- the instructions for practicing the subject methods are generally recorded on a suitable recording medium.
- the instructions may be present in the kits as a package insert or in the labeling of the container of the kit or components thereof.
- the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, such as a flash drive, CD-ROM, or diskette.
- the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, such as via the internet, are provided.
- An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.
- tPA Recombinant tPA (Genentech, South San Fransisco, CA) was used for the tests in this example.
- the thrombus in vitro was made of recalcified mice whole blood at 37 °C for 3h incubation. Thrombolysis was quantified by spectrophotometry at 580 nm wavelength.
- Alteplase/Activase was used for thrombolysis.
- Zn 2+ , Ca 2+ , Fe 3+ , and Fe 2+ were added together with tPA accordingly.
- EDTA was used for ion chelation.
- Rose Bengal 4,5,6,7- tetrachloro-2 * ,4',5',7'-tetraiodofluorescein
- local light exposure were used to introduce photo- thrombosis at the femoral artery.
- Thrombolysis was monitored and quantified by microscopy with software.
- Citrated blood of male CD1 mice was purchased from Alternative research (46430 Peary Court Novi, MI 48377) and BioChemed services (172 Linden Drive, SuitelOl, Winchester, VA 22601). Blood arrived on the next day of harvest and was stored in 4 °C. Citrated blood was used in 3 days due to its decreased clotting ability. An aliquot of 200 ⁇ blood was placed in 0.5 ml tubes and recalcified with 3 ⁇ of 1M CaC . The blood samples were incubated in 0.5 ml centrifuge tubes at 37 °C for 3 hours. Blood clots were gently rinsed by saline 3 times and then transferred to custom-modified cuvettes for measurement of absorbance.
- Custom-modified cuvettes were designed for the absorbance measurement.
- a schematic diagram of these modified cuvettes is shown in FIG. 3A.
- a nylon web was placed at the narrowed part of the cuvette to separate the cuvette into an upper chamber and a lower chamber.
- the lower chamber was where the light passed through during spectrophotometric measurement. The optical intensity change of the light was detected and shown as absorbance value.
- the upper chamber was to hold the blood clot from interfering with the measurement.
- Cuvettes were filled with tPA in 1.5 ml saline solution.
- the lysis treatments were tPA, tPA plus EDTA, and tPA plus metal ions (Zn 2+ , Ca 2+ , Fe 3+ , or Fe 2+ ).
- a spectrophotometer (Biomate3) from Thermo Spectronic (Waltham, MA, USA) was used to test the most sensitive wavelength for hemoglobin at 500 nm to 600 nm. The peaks of absorbance were between 540 nm and 580 nm, which was consistent with previous hemoglobin studies. The wavelength of 580 nm was chosen to measure the absorbance as the optimal wavelength. Samples (cuvettes with blood clots and lysis treatments dissolved in saline) were placed in the spectrophotometer. Saline was used to set up the absorbance baseline. The absorbance of each sample was measured every 5 minutes, for up to 1 hour. The absorbance change between two time points divided by the time duration was considered the rate of lysis.
- the CD1 mouse was anesthetized by intraperitoneal (IP) injection with a cocktail of ketamine, xylazine, and aceptromazine.
- the anesthesia cocktail was made by Ketamine (100 mg/ml) 1 ml, Xylazine (20 mg/ml) 1 ml, Aceptromazine (10 mg/ml) 0.3 ml, and sterile water or saline 7.7 ml. According to the body weight, 6.5 ⁇ /g anesthesia cocktail was given through IP injection.
- the mouse in surgical plane anesthesia was placed on dorsal recumbency on a heat plate connected with ATC 1000 animal temperature controller (World Precision Instruments, 175 Sarasota Center Boulevard, Sarasota, FL 34240-9258 USA).
- ATC 1000 animal temperature controller World Precision Instruments, 175 Sarasota Center Boulevard, Sarasota, FL 34240-9258 USA.
- the femoral artery of the mouse was exposed, followed by the intravenous injection of Rose Bengal (30 mg kg).
- Cold white light that was provided by a Fiber-Lite Illuminator through a probe in 2.16 mm diameter (Dolan-Janner Industries) was placed on the femoral artery.
- the light intensity was 1300 ⁇ W/cm 2 .
- the duration of light exposure was 20 minutes.
- tPA Occlusion of the femoral artery was observed at the location of light exposure, as a dark blood clot and emptiness observed downstream.
- 2 mg/kg tPA was given to the mouse with 0.01 mg as initial bolus, then 30-minute perfusion of the rest via Syringe Infusion Pump 22 (Harvard Apparatus, Holliston, MA).
- Half dose of tPA was lmg/kg, with 0.01 mg as initial bolus and 30-minute perfusion of the rest.
- Ethylenedinitrilo-tetraacetic acid was purchased from Eastman (Kingsport, Tennessee). Rose Bengal and Ethylenediaminetetraacetic acid disodium-calcium salt (CaEDTA) were purchased from Sigma Aldrich (St Louis, MO). Alteplase/Activase (tPA) was purchased from Genentech (South San Francisco, CA). All chemicals were dissolved in saline unless stated otherwise.
- the amount of hemoglobin in a solution can be measured by a spectrophotometer and shown as absorbance.
- absorbance The more hemoglobin contained in a sample, the more opaque the sample becomes. Therefore, a sample yields increasing absorbance value when hemoglobin keeps being released.
- the blood clot lysis thrombolysis
- the thrombolysis of vehicle was also measured.
- the vehicle showed an extremely low level of thrombolysis (FIG. 4B).
- the measurement of absorbance was performed every 5 minutes.
- the absorbance change per minute was calculated as the velocity of the thrombolysis reaction.
- the amplitudes of rate were depicted in arbitrary units.
- the rate of thrombolysis started to increase after 10 minutes and reached the maximum at 20-25 minutes (FIG. 4C).
- Fe 3+ is not as stable as Fe 2+ . Without wishing to be bound by theory, it is believed this is why Fe 2+ was seen to be more effective at inhibition of thrombolysis than Fe 3+ was. Ca 2+ did not affect thrombolysis of tPA.
- Zn 2+ inhibited thrombolysis most consistently in a dose-dependent manner.
- the inhibition effect of Fe 2+ is significant and saturated at 100 ⁇ , with no further inhibition at 200 ⁇ .
- Fe 3+ yielded mild but significant inhibition only at 100 ⁇ (FIGS. 5A-5I).
- Fe 3+ showed a slight effect of promotion on tPA, and only showed consistent inhibition at ⁇ . These results indicate that Zn 2+ acts as a reliable inhibitor in thrombolysis, by reducing the rate of the tPA reaction.
- EDTA was used as a reliable and high-affinity zinc and iron chelator. Blood clots were assigned into two groups. One group was treated with tPA alone. The other group was treated with EDTA (5 mM) together with tPA. The EDTA group significantly augmented the amount of thrombolysis from 20 minutes of the reaction (FIG. 7A).
- Photothrombosis is to introduce in vivo blood clotting by light exposure.
- Rose Bengal is a photosensitive chemical producing singlet oxygen under light exposure. Singlet oxygen breaks down endothelial cells of the blood vessel and initiates thrombosis.
- the femoral artery runs superficially in the hind limb of mice (FIG. 8A).
- the occlusion of the femoral artery was achieved by a photothrombotic method.
- Rose Bengal was systematically delivered through the tail vein followed by 20 minutes of light exposure (intensity: 1300 on top of the femoral artery. The successful occlusion was shown after light exposure as a dark blood clot in exposed location and emptiness of the artery downstream (FIG. 8B).
- tPA The dose of tPA was given by body weight through 30 minutes of continuous intravenous perfusion which was preceded by a tPA bolus. Images of the femoral artery were acquired every 10 minutes under a dissection microscope. The blood clot in the femoral artery was initially dark, and gradually became lighter during the tPA treatment. The reperfusion was observed as blood refilling in the previous empty downstream region in the femoral artery (FIG. 8C), which was later confirmed by cutting the artery downstream of the occlusion. Bleeding was considered as successful reperfusion of the artery. In some cases, reperfusion was not achieved.
- EDTA the high affinity chelator of zinc and iron, also combines with calcium.
- CaEDTA calcium saturated EDTA
- CaEDTA was used in in vivo experiments instead of EDTA to minimize calcium disturbance. CaEDTA was applied so that normal calcium concentration was maintained. Calcium is known to play an important role in physiological functions and is an important factor contributing to coagulation.
- thrombolysis agents were given through intravenous perfusion.
- Three different treatments which were tPA (20 mg kg), half dose of tPA (10 mg kg), and half dose of tPA plus CaEDTA (30 mg/kg), were given accordingly. Images of the occluded femoral artery were taken every 10 minutes since the intravenous perfusion started.
- ImagePro was used to analyze the speed of thrombolysis of tPA treatment and half dose of tPA (1 ⁇ 2tPA) co-administrated with CaEDTA, which is indicated as the change of light transmission. Although two treatments yielded a similar rate of reperfusion (FIG. 10A, Table 1), 1 ⁇ 2 tPA together with CaEDTA showed faster thrombolysis during the first 20 minutes (FIG. 11). The data revealed that ion chelation not only improved thrombolysis outcomes of tPA, but also accelerated the thrombolysis process.
- This example demonstrates that zinc and iron inhibit tPA-induced thrombolysis by reducing the overall effectiveness of tPA.
- the kinetics of thrombolysis was quantified by using spectrophotometry in vitro.
- the removal of zinc and iron with metal ion chelation increased tPA efficacy and promoted tPA-induced thrombolysis of the femoral artery thrombus in vivo.
- Erythrocytes contain 2-3 g iron, or about 2/3 of the total iron contained in the body, with hemoglobin as one of the major sites of storage. Iron is an important factor in blood coagulation. The erythrocyte is another major composite in the clot. During thrombolysis, the release of hemoglobin contributes to locally high concentration of Fe 3+ and Fe 2+ . In this example, Fe 3+ was observed to postpone the maximum velocity of thrombolysis at 100 ⁇ dose (FIG. 6B). At 200 ⁇ , Fe 3+ significantly reduced the efficacy of tPA-induced thrombolysis (FIG. 6C).
- Fe 2+ showed more severe inhibition by reducing velocity of the thrombolysis reaction than Fe 3+ at 100 ⁇ and 200 ⁇ (FIGS. 6H, 61). Without wishing to be bound by theory, it is believed that when iron is binding to proteins, the bond distance generated by trivalent iron (Fe 3+ ) is longer than that generated by divalent iron (Fe 2+ ). Therefore, Fe 2+ binding with proteins is more stable.
- Fe 2+ is that iron blocks the fibrinolysis pathway by either binding and inhibiting tPA like zinc, or by blocking the pathway of fibrin degradation.
- the in vitro results of this example showed no effect of inhibition on thrombolysis when adding 10 ⁇ of Fe 3+ or Fe 2+ (FIGS. 5A, 5G).
- the explanation is that increase of iron may promote plasmin activity on the cell surface.
- the inhibition effect of iron overcomes the promotion effect by suppressing fibrinolytic enzymes and accelerating thrombosis.
- reversible iron binding to fibrinogen mechanistically explains a significant portion of coagulation kinetic and ultrastructural hypercoagulability.
- CaEDTA promotes thrombolysis by augmenting efficacy of tPA-mediated thrombolysis.
- the efficacy of thrombosis which is represented by the maximum velocity, is increased by 55% by EDTA (FIG. 7B).
- EDTA EDTA
- the enhancement of thrombolysis by EDTA is because of Zn 2+ and Fe 3+ chelation, not Fe 3+ , drop. This is because the application of Fe 3+ has little effect on tPA-induced thrombolysis.
- Fe 3+ has a much higher binding affinity to EDTA than Zn 2+
- Zn 2+ is able to displace Fe 3+ -EDTA.
- Zn 2+ reduces FeEDTA-mediated oxidation by 90% when Zn 2+ is added in 1 : 1 molar ratio to Fe 3+ .
- the mechanism of displacement of Fe 3+ from EDTA by Zn 2+ is not settled. It may involve hydrolysis-aided dissociation of Fe 3+ , or the reduction of Fe 3+ (as a redox-active ion) to Fe 2+ which is outcompeted by Zn 2+ at binding EDTA.
- FIGS. 9A-9B ion chelation improves reperfusion outcomes in vivo after photothrombosis of the artery.
- FIG. 9A shows representative sequenced images of tPA-induced thrombolysis in the femoral artery (outlined by dash lines). (Scale bar: 0.5 mm.)
- FIG. 9B shows sequenced images of thrombolysis analyzed by ImagePro and presented as the change of light transmission every 5 minutes during tPA perfusion. Reperfused cases generate a positive change in light transmission, indicating the blood clot being lysed gradually. Thrombosis from non- perfused cases generate a negative change of light transmission due to unsuccessful lysis. The two groups have less than 1% overlap (p ⁇ 0.01).
- a significant superior effect of thrombolysis can be seen when chelation is combined with tPA, as compared to tPA being used alone (FIGS. 9A-9B).
- a half dose of tPA plus CaEDTA achieved a similar reperfusion rate to a full dose of tPA alone (Table 1, FIG. 10A), demonstrating that CaEDTA increases the potency of tP A- mediated thrombolysis.
- the measurement of light transmission of the thrombosis showed that the half dose of tPA together with CaEDTA lysed the blood clot faster than the full dose of tPA (FIG. 11).
- metal ion chelators such as EDTA increase the efficacy of thrombolysis in vitro.
- tPA tPA-deficient mice
- tPA-deficient mice have reduced edema size.
- cytotoxicity of tPA contributes to neuronal death. Therefore, by reducing the therapeutic dose of tPA, co- application of ion chelation can reduce side effects of thrombolysis, and can extend the window of its clinical application.
- compositions and methods disclosed herein are defined in the above examples. It should be understood that these examples, while indicating particular embodiments of the invention, are given by way of illustration only. From the above discussion and these examples, one skilled in the art can ascertain the essential characteristics of this disclosure, and without departing from the spirit and scope thereof, can make various changes and modifications to adapt the compositions and methods described herein to various usages and conditions. Various changes may be made and equivalents may be substituted for elements thereof without departing from the essential scope of the disclosure. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the disclosure without departing from the essential scope thereof.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compositions and methods involving the co- application of a thrombolytic drug and a metal ion chelator are described.
Description
TITLE
Metal Ion Chelation for Enhancing the
Effect of Tissue Plasminogen Activator (tPA) in Thrombolysis
RELATED APPLICATIONS
[0001] This application claims priority to US Provisional Application Ser. No. 62/157,808, filed under 35 U.S.C. § 111(b) on May 6, 2015, the disclosure of which is incorporated herein by reference in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with no government support. The government has no rights in this invention.
BACKGROUND OF THE INVENTION
[0003] Ischemic stroke is the rapid loss of brain function because of the interruption of blood flow, and subsequently brain damage from oxygen-glucose deprivation due to thrombosis or embolism. Stroke is the second leading cause of death worldwide according to the World Health Organization, and the fifth leading cause of death in the US according to the Centers for Disease Control. Furthermore, it is a leading cause of serious long-term disability. Therefore, stroke has a significant impact and burden on individuals, the health care system, and society. Early and adequate medical intervention is critical for improving stroke outcomes. However, the only drug approved by FDA for treatment of acute thrombotic stroke so far is tissue plasminogen activator (tPA), referred to as the Gold Standard by the American Stroke Association.
[0004] The treatment of tPA, a thrombolytic agent, lyses the clot and reperfuses the occluded artery, which is important for saving neurons by improving blood flow to the part of the brain being deprived of blood flow under stroke. Unfortunately, only 1-3% of stroke patients in the US receive this therapy because of the narrow time window for, and severe side effects from, using tPA. Though tPA is effective at dissolving the blot clot which causes a stroke, tPA can dissolve other tissues as well, thereby causing hemorrhaging and other adverse effects. The most deadly and damaging side effect of tPA is the risk of intracranial bleeding or hemorrhage, which deteriorates the outcome of stroke. Since tPA dissolves walls of blood vessels, tPA at higher dosages significantly increases the risk of hemorrhage. For that reason, the dose of tPA and its overall administration are under tight control, while the effect of thrombolysis may be compromised. Thus, there are needs in the art for new and improved methods and compositions for the treatment of ischemic stroke, including methods that would increase the efficacy of tPA, improve the rate of successful thrombolysis by tPA, or reduce the side effects caused by tPA.
SUMMARY OF THE INVENTION
[0005] Provided herein is a composition comprising an effective amount of a thrombolytic drug, at least one metal ion chelator capable of chelating zinc or iron, and a pharmaceutically acceptable excipient, diluent, or carrier. In certain embodiments, the thrombolytic drug comprises tissue plasminogen activator (tPA). In certain embodiments, the thrombolytic drug comprises streptokinase. In certain embodiments, the metal ion chelator is capable of chelating both zinc and iron. In certain embodiments, the metal ion chelator comprises ethylenediaminetetra-acetic acid (EDTA). In particular embodiments, the EDTA comprises calcium saturated EDTA (CaEDTA). In certain embodiments, the effective amount of the thrombolytic drug is less than an amount of the thrombolytic drug needed to be effective in the absence of the at least one metal ion chelator. In certain embodiments, the effective amount of the thrombolytic drug ranges from about 0.25 mg/kg to about 20 mg kg. In certain embodiments, the effective amount of the thrombolytic drug is about 2 mg kg. In certain embodiments, the effective amount of the thrombolytic drug is about 1 mg/kg. In certain embodiments, the effective amount of the thrombolytic drug is about 0.5 mg/kg. In certain embodiments, the at least one metal ion chelator is present at a concentration ranging from about 1 μΜ to about 100 mM . In certain embodiments, the composition further includes a second metal ion chelator capable of chelating zinc or ion. In certain embodiments, the metal ion chelator comprises N,N,N',N'-tetrakis(2-pyrdiylmethyl) ethylenediamine (TPEN). In certain embodiments, the metal ion chelator comprises EDTA and TPEN. In certain embodiments, the composition further includes an additional agent selected from the group consisting of: aspirin, heparin, coumarins (such as warfarin), clopidogrel, oxalate, citrate, hirudin, and combinations thereof.
[0006] Further provided is a method of treating a clotting event, the method comprising the steps of administering an effective amount of a metal ion chelator to a patient having a clotting event, and administering an effective amount of a thrombolytic drug to the patient to treat the clotting event. In certain embodiments, the thrombolytic drug comprises tissue plasminogen activator (tPA). In certain embodiments, the metal ion chelator and the thrombolytic drug are administered simultaneously. In particular embodiments, the metal ion chelator and the thrombolytic drug are in a single composition. In certain embodiments, the metal ion chelator and the thrombolytic drug are administering sequentially. In certain embodiments, the clotting event is selected from the group consisting of: stroke, myocardial infarction, vein thrombosis, and pulmonary embolism. In certain embodiments, the clotting event is a stroke, and the thrombolytic drug is tPA. In particular embodiments, the effective amount of the tPA is about 0.5 mg/kg or higher. In certain embodiments, the metal ion chelator comprises EDTA. In particular embodiments, the metal ion chelator comprises calcium saturated EDTA (CaEDTA). In certain embodiments, the metal ion chelator comprises TPEN. In certain embodiments, the thrombolytic drug comprises
streptokinase. In particular embodiments, the effective amount of streptokinase ranges from about
10,000 units to about 100,000,000 units. In certain embodiments, the metal ion chelator comprises EDTA and TPEN.
[0007] Further provided is a kit for preparing a composition, the kit comprising a first container housing a thrombolytic drug, and a second container housing a metal ion chelator. In certain embodiments, the metal ion chelator comprises EDTA and the thrombolytic drug comprises tPA. In certain embodiments, the kit further includes a syringe.
BRIEF DESCRIPTION OF THE DRAWING
[0008] The patent or application file may contain one or more drawings executed in color and/or one or more photographs. Copies of this patent or patent application publication with color drawing(s) and/or photograph(s) will be provided by the U.S. Patent and Trademark Office upon request and payment of the necessary fees.
[0009] FIG. 1: Diagram of embolic or thrombotic stroke and stroke treatment with tPA.
[0010] FIG. 2: Diagram of embolic or thrombotic stroke and stroke treatment with tPA versus with a composition having a metal ion chelator and one -half the otherwise required dosage of tPA.
[0011] FIGS. 3A-3C: The set-up for blood clot lysis (thrombolysis) in vitro spectrophotometric measurement. FIG. 3A shows a schematic diagram of the custom-modified cuvette used. FIG. 3B shows a photograph of the cuvettes at the start of thrombolysis. Each blood clot was formed from 200 recalcified CDl mouse blood, and transferred into the cuvette. The color of lystate at this point was clear, and the absorbance was low. FIG. 3C shows a photograph of the cuvettes after 60 minutes of thrombolysis. Cuvette 1, 2, and 3 represented lysate of three doses of tPA (0.005 mg, 0.01 mg, and 0.05 mg).
[0012] FIGS. 4A-4D: The clot-lysis represented by absorbance at 1 hour in different
thrombolysis agents, measured by spectrophotometry at 580 nm wavelength. FIG. 4A shows the thrombolysis curve of tPA. FIG. 4B shows quantified thrombolysis at one hour treatment with tPA and tPA plus different metal ions. The dose of tPA was 0.01 mg. ZnCl2: 200 μΜ. FeC , FeC : 100 μΜ. FIG. 4C shows the rate of thrombolysis of tPA. FIG. 4D shows the maximum rate of thrombolysis of tPA and tPA plus metal ions. Saline was used as a vehicle in these treatments. Data were shown as mean + SEM. The numbers of samples tested: 22 in tPA, 13 in (tPA + EDTA), 6-9 in tPA with Zn2+, Fe2+, and Fe3+, and 4 in saline. * p < 0.05. *** P < 0.001.
[0013] FIGS. 5A-5I: Quantified clot lysis in 60 min shown as absorbance increase measured by spectrophotometry at 580 nm. n = 22 in tPA alone. FIGS. 5A-5C show thrombolysis of tPA compared to tPA plus different doses of Fe3+. n = 6-10 per group of (tPA + Fe3+). FIGS. 5D-5F show thrombolysis of tPA compared to tPA plus different doses of Zn2+. n=6-9 per group of (tPA + Zn2+). FIGS. 5G-5I show thrombolysis of different doses of Fe2+ with tPA. n=6-9 per group of (tPA + Fe2+). * P< 0.05, *** P< 0.001.
[0014] FIGS. 6A-6I: The reaction velocity of thrombolysis in different treatments, n = 22 in
tPA alone group. FIGS. 6A-6C show the rate of thrombolysis in different doses of Fe + plus tPA. n = 6-10 per group of (Fe3+ + tPA). FIGS. 6D-6F show the rate of thrombolysis in different doses of Zn2+ plus tPA. n = 6-9 per group of (Zn2+ + tPA). FIGS. 6G-6I show the rate of thrombolysis in different doses of Fe2+ plus tPA. n=6-9 per group of (Fe2+ + tPA). * P< 0.05.
[0015] FIGS. 7A-7B: Effect of EDTA on clot-lysis of tPA. Ion chelation promotes tPA-induced thrombolysis. These graphs show the effect of EDTA on tPA-induced thrombolysis in 60 minutes. FIG. 7A shows quantified thrombolysis represented by change of optical density in 60 minutes. FIG. 7B shows the velocity of thrombolysis. Values are mean + SEM. n = 22 in tPA, n = 13 in (tPA + EDTA). * p < 0.05. The numbers of samples tested: 22 in tPA, and 13 in (tPA + EDTA).
[0016] FIGS. 8A-8C: Clot-lysis in vivo. FIG. 8A shows the exposure of the femoral artery on the CD1 mouse. The arrow shows the femoral artery. Scale bar: 1 cm. FIG. 8B shows photo thrombosis formed in the femoral artery (shown as the arrow), leaving the downstream blood-free (outlined by dash lines). FIG. 8C shows thrombolysis after tPA perfusion. Scale bar: 1 mm
[0017] FIGS. 9A-9B: Ion chelation improves reperfusion outcomes after photothrombosis of artery. These figures show real-time thrombolysis in vivo. FIG. 9A shows thrombolysis at each time point (0, 10, 20, 30, and 40 min), with different tPA treatments (tPA, ½ tPA and ½ tPA + CaEDTA). Femoral arteries were outlined by dash lines. Scale bar, 0.5mm. FIG. 9B shows the change of light transmission in each thrombosis. Empty dots represent data from reperfused cases. Black square dots represent data from non-reperfused cases. P < 0.01 between those two groups.
[0018] FIGS. 10A-10B: Table (FIG. 10A) and graph (FIG. 10B) showing the percentage of reperfusion versus non-reperfusion in vivo in different thrombolytic treatments. There were more reperfused cases in treatments of tPA and (½ tPA + CaEDTA). n = 10-12 in each group. *p<0.05 between (½ tPA) and (½ tPA + CaEDTA).
[0019] FIG. 11: Change of thrombolysis in tPA treatment and (½ tPA + CaEDTA). n = 7 in tPA group, n = 9 in (½ tPA + CaEDTA) group. *P<0.05.
[0020] FIG. 12: Graph showing the percentage of blood clot lysis from different treatments. The metal ion chelator CaEDTA or TPEN increased clot lysis when co-applied with streptokinase (SK), compared to lysis of the control groups (SK, CaEDTA, or TPEN alone). The addition of chelator without SK showed little to no lysis.
[0021] FIG. 13: Graph showing the blood clot lysis from different treatments. The addition of zinc (200 μΜ) inhibited the streptokinase (SK)-induced clot lysis when compared to the lysis of the streptokinase treatment group.
DETAILED DESCRIPTION OF THE INVENTION
[0022] Throughout this disclosure, various publications, patents and published patent
specifications are referenced by an identifying citation. The disclosures of these publications,
patents and published patent specifications are hereby incorporated by reference into the present disclosure in their entirety to more fully describe the state of the art to which this disclosure pertains.
[0023] Although tPA is the only drug approved by the FDA for treatment of acute thrombotic stroke, and the standard of care for treatment of acute thrombotic stroke, it must be administered as early as possible after the onset of stroke symptoms in order to be effective in the treatment of ischemic stroke. Protocol guidelines require its use intravenously within the first three hours of the event, after which its detrimental side effects may outweigh its benefits. Therefore, the patient needs to present in the hospital soon after the onset of stroke symptoms, which is almost impossible. For this reason, only about 1-3% of stroke patients in the United States receive this therapy.
[0024] The bloodstream contains and transports a large variety of ions, including major trace elements zinc and iron. The dyshomeostasis of these metal ions is closely correlated to the pathogenesis of cerebral ischaemia, contributing significantly to brain damage in stroke. Zinc (Zn2+) has been correlated to cell damage in stroke. Without wishing to be bound by theory, it is believed that both zinc and iron are involved in the clotting of blood. Iron is important for red blood cells and plays role in coagulation. Similarly, zinc deficiency can lead to increased bleeding tendency and delayed wound healing by poor platelet aggregation.
[0025] The concentration of total zinc in blood plasma is around 15 μΜ or 60-120μg /100ml, which is bound predominantly to blood proteins. A substantial amount of zinc has also been found in various cellular compartments, vesicles, or vacuoles. Zn is stored in many types of cells, including platelets, which are responsible for making clots. Zn concentration is high (in the micromolar range) in platelets. In the bloodstream, the most zinc-enriched site is the a-granule of platelets, where the zinc concentration reaches 500μΜ. This is almost a 30-fold higher level of zinc in platelets than in the serum. Like zinc, iron also has intracellular and extracellular repositories. The amount of serum iron is 60-170 μg /100ml, which is slightly higher than serum zinc. The hemoglobin of erythrocytes, on the other hand, is the major site of iron storage. About 65% of the iron in the body is bound up in hemoglobin, where iron is bound with heme. Iron is strictly regulated by the binding of proteins such as transferrin in the bloodstream and ferritin in cell plasma.
[0026] The platelets and erythrocytes are physiologically important for thrombus formation. During the clot formation, a large amount of zinc releases from platelets and leads to a surge in zinc concentrations in the local microenvironment of an expanding thrombus, which promotes fibrin formation and triggers key signalling events that lead to platelet aggregation. Together with fibrin, aggregated platelets and erythrocytes are major components in thrombus composition. Because platelets and erythrocytes store a substantial amount of zinc (in platelet granules) and iron (in hemes), thrombi become a source of these metal ions as they are "trapped" in the thrombi. The
precise role of these thrombus ions is not known. However, without wishing to be bound by theory, it believed that zinc enhances the production of fibrin, and free iron promotes blood coagulation and increases fibrinogen strength. Hence, the presence of increasing free zinc and iron creates resistance to thrombolysis.
[0027] Zinc is part of the processes of thrombosis and thrombolysis, and is involved in several steps of blood coagulation. For example, zinc triggers platelets aggregation. High concentrated zinc is packed in a-granules of platelets, which make platelets the highest zinc-containing cells among hematocytes. Zinc can affect hemostasis by directly affecting the function of platelets. The activated platelets secrete the contents of these granules through platelet exocytosis. During coagulation and thrombosis, the platelets undergo the cascade of activation, adhesion, and aggregation as the important part of the clot formation process. Zinc has been shown to induce platelet aggregation and affect ADP-induced aggregation in a synergistic manner. Zinc deficient rodents and humans have all displayed an increase in bleeding time and a decrease in platelet function. Zinc interacts with factor FXII and may be an essential cofactor. When local zinc concentration is 10-30 fold higher than plasma, zinc activates FXII and potentiates blood clotting. Zinc has been shown to regulate fibrinolytic pathways and to enhance the production of fibrin. When it comes to intensifying polymerization of fibrin oligomer, zinc is an introducer stronger than calcium. Furthermore, zinc prevents thrombolysis by inhibiting fibrin clearance. The presence of a substantial amount of zinc provides a positive feedback mechanism for platelet aggregation, the propagation of coagulation, and stabilizing the blood clot.
[0028] Another ion that is important for thrombolysis is iron. Generally, an adult human contains 3-4 grams of iron with 2-3 grams in erythrocytes. Iron is also strictly regulated by the binding of proteins such as transferring in the bloodstream and ferritin in cell plasma. Free iron promotes blood coagulation. Like zinc, iron also has intracellular and extracellular repositories, which are able to yield a locally high level of free Fe3+/Fe2+ during thrombolysis.
[0029] Platelets (storing zinc) collapse during clot formation, creating a significant amount of Zn in the clot. Without wishing to be bound by theory, it is believed that during thrombolysis, zinc and iron are dissociated from the blood clot, creating a focal high concentration of these ions. When a thrombolytic drug, such as tPA, dissolves the clot, the dissolution of the clot releases the Zn from the clot. Without wishing to be bound by theory, it is believed that this released Zn interacts with the thrombolytic drug. Similarly, a high concentration of Fe is present in blood clots, such that when a thrombolytic drug dissolves a blood clot, the dissolution of the clot releases Fe from the clot. Without wishing to be bound by theory, it is believed that this released Fe interacts with the thrombolytic drug. More generally, it is believed that there are interactions between ions, such as zinc and iron, and thrombolysis mediated by a thrombolytic drug such as tPA.
[0030] The zinc increase triggers platelets' activation and blood coagulation. The examples
herein describe the effect of zinc and iron on the tPA-induced thrombolysis of a whole blood clot measured in vitro, which is a physiologically relevant model. The results show that the application of zinc or iron significantly inhibits tPA-induced thrombolysis. The therapeutic effect of metal ion chelation on tPA-induced thrombolysis in vivo was also evaluated. As seen from the examples, because zinc and iron inhibit tPA-induced thrombolysis, the chelation of these ions enhance its action. Removing zinc, removing iron, or removing both zinc and iron, with metal ion chelators accelerates tPA-mediated thrombolysis. Removing zinc, removing iron, or removing both zinc and iron, with metal ion chelators also reduces the necessary dose of tPA. The chelation removes not only chelatable ions in the serum but also free zinc and iron dissociated from the blood clots where tPA is inducing thrombolysis. As described in the examples, the co- application of a metal ion chelator facilitates the action of tPA on the thrombolysis of a femoral artery thrombus. The chelation accelerates the rate of tPA-induced thrombolysis, enhances overall tPA-induced thrombolysis, and reduces tPA doses necessary for effective thrombolysis. Thus, described herein are compositions and methods that utilize the co-application of a chelator and a thrombolytic drug (such as tPA) to improve the efficacy, potency, and safety of the thrombolytic drug in the treatment of a clotting event such as a stroke.
[0031] In accordance with the above, provided herein are compositions that include a
thrombolytic drug and at least one metal ion chelator, as well as methods that involve the co- application (either simultaneously or sequentially) or a thrombolytic drug and at least one metal ion chelator. The presence of the metal ion chelator can enhance the potency and efficacy of the thrombolytic drug, and can reduce the necessary concentration of the thrombolytic drug. In some embodiments of the compositions, the composition can have the same efficacy as a certain concentration of the thrombolytic drug alone when it contains one-half the concentration of the thrombolytic drug in combination with a metal ion chelator.
[0032] Both zinc and iron inhibit tPA-induced thrombolysis by postponing the maximum effect or decreasing tPA efficacy. The examples herein show further that the removal of zinc and/or iron, by the co-application of a metal ion chelator with a thrombolytic drug, enhances the effect of the thrombolytic drug-induced thrombolysis in vivo. Though tPA is described for exemplary purposes, it is to be understood that the present disclosure is not limited to tPA, and is not limited to applications involving clotting events in the brain. In fact, a metal ion chelator may be combined and/or co-applied with any other thrombolytic drugs to improve their potency and efficacy in treating, for example, myocardial infarction, vein thrombosis, or pulmonary embolism. To illustrate this broad effect of metal ion chelators, the examples herein include an evaluation of a metal ion chelator with streptokinase. Streptokinase is a thrombolytic drug used for treating myocardial infarction and pulmonary embolism. As the examples show, co-application of a metal ion chelator was able to increase clot lysis caused by streptokinase (FIG. 12) as well as tPA
(FIGS. 7A-7B, FIGS. 10A-10B, FIG. 11).
[0033] The compositions and methods herein can include any thrombolytic drugs (or combinations thereof), and are not limited to the treatment of strokes. Suitable thrombolytic drugs include, but are not limited to: tPA, streptokinase (Kabiknase, Streptase) or recombinant streptokinase, reteplase (Retavase), tenecteplase (TNKase), anistreplase (Eminase), urokinase (Abbokinase), single-chain urokinase-type plasminogen activator, plasminogen acetylation- streptokinase activate complex, alteplase, PPA, Batroxobin, Sak, venom thrombolytic enzymes, or combinations thereof. Further, it is understood that reference to "tissue plasminogen activator" and "tPA" can include recombinant tissue plasminogen activator (rtPA).
[0034] The thrombolytic drug can be present in the composition at a concentration lower than would be necessary for effective thrombolysis in the absence of a metal ion chelator. Generally, the concentration of the thrombolytic drug in the compositions ranging from about 0.1 mg kg to about 30 mg/kg, or from about 0.25 mg/kg to about 20 mg/kg. In one non-limiting example, the thrombolytic drug is present at a concentration of only about 0.5 mg/kg or higher. In another non- limiting example, the thrombolytic drug is present at a concentration of about 10 mg/kg. When the thrombolytic drug is streptokinase, the effective amount of the streptokinase present in the composition may be expressed as units or international units. As used herein, a "unit" refers to an amount of streptokinase which will liquefy a standard clot of fibrinogen, plasminogen, and thrombin at pH 7.5 at 37 °C in 10 minutes. An "international unit" of streptokinase, on the other hand, is defined as the activity contained in 0.002090 mg of the international standard for streptokinase-streptodornase. In some embodiments, the effective amount of streptokinase in accordance with the present disclosure can range from about 10,000 units to about 100,000,000 units.
[0035] The metal ion chelator can be a chelator capable of chelating zinc (a "zinc chelator"), a chelator capable of chelating iron (an "iron chelator"), or a chelator capable of chelating both zinc and iron. In some embodiments, the composition includes multiple metal ion chelators. In such embodiments, the multiple metal ion chelators can each be zinc chelators, iron chelators, or combinations thereof.
[0036] Suitable zinc chelators include, but are not limited to: ethylenediaminetetra-acetic acid (EDTA); l,3-diaminopropane-N,N,N',N'-tetraacetic acid (DTP A); N,N,N',N'-tetrakis(2- pyrdiylmethyl) ethylenediamine (TPEN); 1,10-phenanthroline; clioquinol; diethyldithiocarbamate (DEDTC), 2,3-dimercapto-l-propanesulfonic acid (DMPS); ethylenediamine-N,N'-diacetic-N,N'- di-B-propionic acid (EDPA); l,2-dimethyl-3-hydroxy-4-pyridinone (DMHP); l,2-diethyl-3- hydroxy-4-pyridinone (DEHP); ethylmaltol (EM), 4-(6-methoxy-8-quinaldinyl- aminosulfonyl)benzoic acid potassium salt (TFLZn); dithiozone; N-(6-methoxy-8-quinolyl)-para- toluenesulfonamide (TSQ); carnosine; deferasirox; trans- l,2-cyclohexane-diamine-N,N,N',N'- tetraacetic acid (CyDTA); dihydroxyethylglycine (DHEG); l,3-diamino-2-hydroxypropane- Ν,Ν,Ν',Ν'-tetraacetic (DTPA-OH); ethylenediamine-N,N'-diacetic acid (EDDA); ethylenediamine-
Ν,Ν'-dipropionic acid (EDDP); ethylenediarnine-N,N'-bis(methylpliosplioriic) acid (EDDPO); N- hydroxy-ethylenediamine-N,N',N'-triacetic acid (EDTA-OH); aminophenol triacetic acid
(APTRA); ethylenediarninetetra(methylenephosplioriic) acid (EDTPO); N,N'-bis(2- hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED); hexamethylene-1,6- diaminetetraacetic acid (HDTA); hydroxyethyliminodiacetic acid (HIDA); iminodiacetic acid (IDA); methyl-EDTA, nitrilotriacetic acid (NTA); nitrilotripropionic acid (NTP),
nitrilotrimethylenphosphonic acid (NTPO); 7,19,30-trioxa-l,4,10,13,16,22,27,33- octaazabicyclo[l 1,11,11] pentatriacontane (O-Bistren); triethylenetetraaminehexaacetic acid (TTHA); ethyleneglycol bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA); l,2-bis(o- aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA); dimercaptosuccinic acid (DMSA); deferoxamine; dimercaprol; zinc citrate; combinations of bismuth and citrate; penicilamine;
succimer; etidronate; ethylenediamine-di (O-hydroxyphenylacetic acid) (EDDHA); trans- 1,2- cyclohexanediaminetetraacetic acid (CDTA); N-(2 -hydro xyethyl) ethylenedinitrilotriacetic acid (HEDTA); N-(2-hydroxyethyl) iminodiacetic acid (HEIDA); 9-(0-carboxyphenyl)-2,7-dichloro- 4,5,-bis[bis(2-pyridylmethyl)-aminomethyl]-6-hydroxy-3-xanthone; 9-(0-carboxyphenyl)-4,5- bis[bis(2-pyridylmethyl)-aminomethyl]-6-hydroxy-3-xanthanone; 9-(0-carboxyphenyl-2-chloro-5- [2-{bis(2-pyridylmethyl)aminomethyl}-N-methylaniline]-6-hydroxy-3-xanthanone; calprotectin; zinc fingers; lactoferrin; ovotransferrin; conalbumin; salts thereof; and combinations thereof. In other embodiments, the zinc chelator is a wild-type apoenzyme or genetically engineered mutant thereof. Examples of the apoenzyme include, but are not limited to, apo-carbonic anhydrase, a S166C mutant, a H36C mutant, or a E117A mutant.
[0037] Suitable iron chelators include, but are not limited to: ethylenediaminetetraacetic acid (EDTA); nitriloacetic acid; diethylenetriaminepentaacetic acid; Ν,Ν'-bis (2-hydroxybenzyl) ethylenediamine-N,N'-diacetic acid (HBED); dimercaptosuccinic acid; 2,3-dimercato-l- propanesulfonic acid (DMPS); alpha lipoic acid (ALA); 8 -hydroxy quinoline derivatives, such as 5- [4-(2-hydroxyethyl)piperazin-l-ylmethyl]-8-hydroxyquinoline; hydro xypyridinones, such as deferiprone; hydroxamates, such as desferrioxamine (DFO); amine carboxylates; catechols;
hydroxpyridinones; pyridoxal isonicotinoly hydrazone (PIH) and derivatives thereof; siderophores, such as enterobactin, parabactin, agrobactin, fluviabactin, vulnibactin, vibriobactin, ferrioxamine B, ferrioxamine E, aerobactin, ferrichrome, and desferrithiocin and its analogues and derivatives; diketones, such as dibenzoylmethane (l,3-dephenyl-l,3-propanedione); beta-diketones, such as hydroxydibenzoyl methane or hydroxymethyldibenzoylmethane; salts thereof; and combinations thereof.
[0038] In certain embodiments, the metal ion chelator is EDTA or a salt thereof, such as
CaEDTA. EDTA is a cell-impermeable metal ion chelator that has extremely high affinity to zinc and iron compared to other biologically relevant ions. Thus, EDTA is both a zinc chelator and an iron chelator. The EDTA stability constants of Zn2+, Fe2+, and Fe3+ are 16.5, 14.3, and 25.1,
respectively. CaEDTA is particularly useful as the metal ion chelator for several reasons. For instance, CaEDTA is more specific for zinc than other ions, such as calcium. Also, CaEDTA is an extracellular, membrane-impermeable chelator, meaning it generally does not cross the cellular membrane and remain inside cells.
[0039] The metal ion chelator can be present in the composition at a concentration ranging from about 1 μΜ to about 500 mM, or from about 10 μΜ to about 100 mM. The metal ion chelator is typically present in the composition at a concentration ranging from about 1 mM to about 20 mM. For example, the concentration of the metal ion chelator can be about 5 mM. In other embodiments, the concentration of the metal ion chelator in the composition ranges from about 10 μΜ to about 1000 μΜ. The concentration of the metal ion chelator can be selected based on the desired use. For instance, the optimal concentration of metal ion chelator present in a composition with tPA, to be used to treat a stroke, may be different from the optimal concentration of metal ion chelator present in a composition with streptokinase, to be used to treat myocardial infarction. The metal ion chelator can increase the efficacy and potency of tPA-mediated thrombolysis, and can expand the time window allotted for tPA treatment without the risk of its side effects.
[0040] Changes in ionic concentration have a vital effect on numerous physiological processes related to blood coagulation and fibrinolysis. Though the compositions and methods described herein can effectively remove some Zn2+ ions, zinc is nonetheless an integral component of thousands of different proteins, none of which are functional if the zinc is removed. Zinc metalloproteins include transcription factors containing zinc fingers, structural proteins, and enzymes from all six enzyme classes. Zinc metalloproteins are present in virtually every cellular organelle of every cell type in the brain and body. Zinc is also important for DNA stabilization and gene expression. Thus, zinc deficiency can be harmful, or even fatal in some situations. Zinc deficiency can lead to increased bleeding tendency. Without wishing to be bound by theory, it is believed that chelating zinc to too low a level can induce seizures or facilitate apoptosis.
Therefore, the compositions and methods herein should be practiced with an understanding of, and respect for, the importance of zinc in the overall body. Similarly, iron is essential for red blood cells, and plays a role in coagulation. Iron deficiency is the most common cause of anemia. Iron deficiency may also cause reduced immunity. Accordingly, certain embodiments of the methods herein involve either monitoring free zinc and/or iron levels in a subject undergoing the treatment, and/or supplementing zinc and/or iron levels during or following the treatment.
[0041] As one non-limiting example, free zinc levels can be monitored through the use of zintrodes. Zintrodes are chemical sensors/probes based on optical fibers which can be used to transmit excitation light from an illumination source to an analyte captured within an area of the probe, and to collect the return signal, either emission or scattering, onto a detector. The fiber optic probe is small and enables in vitro or in vivo real-time monitoring of biological fluids and in vivo implantation. Typically, the zintrode body is made of an inert, biocompatible material, such
as a fluorocarbon, with a port or an area in the wall that is fitted with a material permeable to the analyte (Zn2+), which reacts with a reagent contained within the body of the sensor. Similarly, serum iron levels can be monitored through a standard blood test.
[0042] As another non-limiting example, zinc levels can be supplemented through the
administration of any suitable zinc supplement. Zinc supplements include, but are not limited to, one or more forms of inorganic or organic zinc, or combinations thereof, for oral or parenteral administration, including solid, gel, liposomal, and liquid forms. Non-limiting examples include zinc chloride (ZnC ); tetrabasic zinc chloride (ZnsCkfOEOs); zinc oxide (ZnO); zinc sulfate (ZnS04); zinc proteinates; zinc chelates; zinc amino acid complexes, such as zinc histidine, zinc methionine, or zinc lysine complexes; zinc acetate; zinc ascorbate; zinc aspartate; zinc butyrate; zinc carbonate; zinc citrate; zinc gluconate; zinc glycinate; zinc histidinate; zinc lactate; zinc maleate; zinc picolinate; zinc propanoate; zinc stearate; and zinc succinate. In certain embodiments, the zinc supplements are administered to deliver from about 10 mg to about 400 mg of elemental zinc per day for a desired period of time.
[0043] Similarly, iron levels can be supplemented through the administration of any suitable iron supplement. Commonly available iron supplements generally include a single form of iron.
Examples of common single forms of iron used in iron supplements include iron salt, that is, a salt containing divalent or ferrous iron salt, such as a salt containing trivalent or ferric iron and iron (0) powder, such as carbonyl iron. Iron supplements are available commercially in rapid release dosage forms and in controlled release dosage forms. Rapid release iron supplement dosage forms typically contain a "rapidly dissolving" iron salt. Certain iron salts are significantly more soluble in water and gastrointestinal fluids than other salts and metallic forms of iron. Hence, these more soluble iron salts or "rapidly dissolving" iron salts are incorporated into rapid release iron supplement dosage forms. In certain embodiments, the iron supplements are administered to deliver from about 1 mg to about 45 mg of iron per day for a desired period of time. As another method, consuming meat and fish can help supplement iron levels, as meat and fish generally contain a significant amount of heme iron, which is readily absorbed by humans.
[0044] Furthermore, there is increased free zinc levels following hypoxic stress, which can be a precursor for cell death. Abnormal high zinc levels can cause mitochondrial dysfunction and reinforce apoptotic signaling cascades. Zinc chelation has been shown to be neuroprotective in cellular and animal models. Subarachnoid hemorrhage (SAH) causes excess quantities of hemoglobin and its degradation production product, iron, in the perivascular space. Treatment with an iron chelator has been proven to reduce brain edema, cerebralvasospasm, and neuronal cell death in a rat model of SAH. The effective zinc and iron chelation facilitates tPA-induced thrombolysis and reduces the necessary dose of tPA treatment. Therefore, by co-applying a metal ion chelator and a thrombolytic drug, a smaller dose of the thrombolytic drug (such as 50% than an otherwise effective dose) is needed to achieve a higher rate of reperfusion. Accordingly, the co-
application of a thrombolytic drug and a metal ion chelator (within the same or a separate, co- applied composition) can reduce the adverse effects of tPA, such as hemorrhage. This co- application can also offer additional benefits. For instance, the presence of the metal ion chelator may remove zinc or iron accumulated inside of cells caused by hypoxic stress. Accumulated free iron injures endothelial cells by the production of free radicals. Therefore, the presence of the metal ion chelator can improve neuronal survival by reducing the secondary brain injury or reperfusion brain injury. For example, in the unwanted event of tPA-induced hemorrhage, having a metal ion chelator can reduce the brain damage caused by hemorrhage. Therefore, metal ion chelation can also improve the outcome of thrombolysis by further reducing the adverse effect of a thrombolytic drug such as tPA, as well as the toxicities associated with dissociated zinc and iron. Diverse serial and parallel events contribute to ischemic neuronal cell death. As such, combined treatments that target multiple events for better thrombolytic results are encompassed herein.
[0045] A pharmaceutical composition as described herein may be formulated with any
thrombolytic drug and a metal ion chelator, plus any pharmaceutically acceptable excipients, diluents, or carriers. A composition disclosed herein may comprise different types of carriers depending on whether it is to be administered in solid, liquid, or aerosol form, and whether it needs to be sterile for such routes of administration as injection. Compositions disclosed herein can be administered intravenously, intradermally, transdermally, intrathecally, intraarterially, intraperitoneally, intranasally, intravaginally, intrarectally, intraosseously, periprosthetically, topically (i.e., transdermal), intramuscularly, subcutaneously, mucosally (i.e., intranasally, vaginal, etc.), in utero, orally, topically, locally, via inhalation (e.g., aerosol inhalation), by injection, by infusion, by continuous infusion, by localized perfusion bathing target cells directly, via a catheter, via a lavage, in cremes, in lipid compositions (e.g., liposomes), parenterally (i.e., routes that bypass the alimentary tract, such as by injection or by continuous or discontinuous intra- arterial infusion), compressed into tablets or formulated as elixirs or solutions for convenient oral administration or administration by intramuscular or intravenous routes, formulated as sustained release dosage forms, or by other method or any combination of the forgoing as would be known to one of ordinary skill in the art (see, for example, Remington' s Pharmaceutical Sciences, 2003, incorporated herein by reference).
[0046] The compositions provided herein are useful for treating animals, such as humans, for various embolic or thrombotic conditions and clotting events. A method of treating a human patient according to the present disclosure includes the administration of an effective amount of a thrombolytic drug and a metal ion chelator, or pharmaceutical composition comprising the combination of a thrombolytic drug and a metal ion chelator. In other embodiments, multiple pharmaceutical compositions - a first composition including a thrombolytic drug, and a second composition including a metal ion chelator - are administered. The metal ion chelator and thrombolytic drug can be administered sequentially or simultaneously. When the metal ion
chelator and thrombolytic drug are administered sequentially, there can be a delay of a desired period of time between the first administration and the second administration. Similarly, multiple cycles of sequential administration can be practiced, with or without a significant time delay between cycles.
[0047] When formulated into compositions which may be administered by the oral or rectal routes, or parentarelly, the thrombolytic drug and metal ion chelator can be in the form of, for example, tablets, lozenges, sublingual tablets, sachets, cachets, elixirs, gels, suspensions, aerosols, ointments, for example, containing from 1 to 10% by weight of the active compound in a suitable base, soft and hard gelatin capsules, suppositories, injectable solutions, and suspensions in physiologically acceptable media, or sterile packaged powders adsorbed onto a support material for making injectable solutions.
[0048] The formulations useful for separate administration of the thrombolytic drug and metal ion chelator normally contain at least one compound selected from thrombolytic drugs and metal ion chelators (which may, individually or together, be referred to herein as the active ingredient or active substance) mixed with a pharmaceutically acceptable carrier, or diluted by a carrier, or enclosed or encapsulated by an ingestible carrier in the form of a capsule, sachet, cachet, paper, or other container, or by a disposable container such as an ampoule. The phrases "pharmaceutical" or "pharmacologically acceptable" refer to molecular entities and compositions that produce no adverse, allergic, or other untoward reaction when administered to an animal, such as, for example, a human. A carrier or diluent may be a solid, semi-solid, or liquid material which serves as a vehicle, excipient, or medium for the active therapeutic substance. Some examples of the diluents or carriers which may be employed in the pharmaceutical compositions of the present disclosure are lactose, dextrose, sucrose, sorbitol, mannitol, propylene glycol, liquid paraffin, white soft paraffin, kaolin, fumed silicon dioxide, microcrystalline cellulose, calcium silicate, silica, polyvinylpyrrolidone, cetostearyl alcohol, starch, modified starches, gum acacia, calcium phosphate, cocoa butter, ethoxylated esters, oil of theobroma, arachis oil, alginates, tragacanth, gelatin, syrup, methyl cellulose, polyoxyethylene sorbitan monolaurate, ethyl lactate, methyl and propyl hydro xybenzoate, sorbitan trioleate, sorbitan sesquioleate and oleyl alcohol, and propellants such as trichloromonofluoromethane, dichlorodifluoromethane, and dichlorotetrafluoroethane. In the case of tablets, a lubricant may be incorporated to prevent sticking and binding of the powdered ingredients in the dies and on the punch of the tableting machine. For such purposes there may be employed, for instance, aluminum, magnesium, or calcium stearates, talc, or mineral oil.
[0049] In certain embodiments, a composition and/or additional agent is formulated to be administered via an alimentary route. Alimentary routes include all possible routes of administration in which the composition is in direct contact with the alimentary tract. Specifically, the pharmaceutical compositions disclosed herein may be administered orally, buccally, rectally,
or sublingually. As such, these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard- or soft- shell gelatin capsules, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.
[0050] Solutions of the compositions disclosed herein as free bases or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as
hydroxypropylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof, and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In certain cases the form should be sterile and should be fluid to the extent that easy injectability exists. It should be stable under the conditions of manufacture and storage and may optionally be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, a polyol (i.e., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion, and/or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it may be preferable to include isotonic agents, such as, but not limited to, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption such as, for example, aluminum monostearate, or gelatin.
[0051] For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration. Sterile aqueous media that can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage may be dissolved in 1 mL of isotonic NaCl solution and either added to 1000 mL of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
[0052] Sterile injectable solutions are prepared by incorporating the compositions in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various
sterilized compositions into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, some methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. A powdered composition is combined with a liquid carrier such as, e.g., water or a saline solution, with or without a stabilizing agent.
[0053] Pharmaceutical compositions for topical administration may include the compositions formulated for a medicated application such as an ointment, paste, cream, or powder. Ointments include all oleaginous, adsorption, emulsion, and water-soluble based compositions for topical application, while creams and lotions are those compositions that include an emulsion base only. Topically administered medications may contain a penetration enhancer to facilitate adsorption of the active ingredients through the skin. Suitable penetration enhancers include glycerin, alcohols, alkyl methyl sulfoxides, pyrrolidones and luarocapram. Possible bases for compositions for topical application include polyethylene glycol, lanolin, cold cream, and petrolatum as well as any other suitable absorption, emulsion, or water-soluble ointment base. Topical preparations may also include emulsifiers, gelling agents, and antimicrobial preservatives as necessary to preserve the composition and provide for a homogenous mixture. Transdermal administration of the compositions may also comprise the use of a "patch." For example, the patch may supply one or more compositions at a predetermined rate and in a continuous manner over a fixed period of time.
[0054] In certain embodiments, the compositions are suitable for delivery by eye drops, intranasal sprays, inhalation, and/or other aerosol delivery vehicles. Methods for delivering compositions directly to the lungs via nasal aerosol sprays have been described in U.S. Patents 5,756,353 and 5,804,212 (each specifically incorporated herein by reference in their entirety). Likewise, the delivery of drugs using intranasal microparticle resins (Takenaga et al., 1998) and lysophosphatidyl-glycerol compounds (U.S. Patent 5,725, 871, specifically incorporated herein by reference in its entirety) are also well-known in the pharmaceutical arts and could be employed to deliver the compositions described herein. Likewise, transmucosal drug delivery in the form of a polytetrafluoroetheylene support matrix is described in U.S. Patent 5,780,045 (specifically incorporated herein by reference in its entirety), and could be employed to deliver the
compositions described herein.
[0055] It is further envisioned the compositions disclosed herein may be delivered via an aerosol. The term aerosol refers to a colloidal system of finely divided solid or liquid particles dispersed in a liquefied or pressurized gas propellant. The typical aerosol for inhalation consists of a suspension of active ingredients in liquid propellant or a mixture of liquid propellant and a suitable solvent. Suitable propellants include hydrocarbons and hydrocarbon ethers. Suitable containers will vary according to the pressure requirements of the propellant. Administration of
the aerosol will vary according to subject's age, weight, and the severity and response of the symptoms.
[0056] The actual dosage amount of a composition disclosed herein administered to an animal or human patient can be determined by physical and physiological factors such as body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, idiopathy of the patient, and the route of administration. Depending upon the dosage and the route of administration, the number of administrations of a preferred dosage and/or an effective amount may vary according to the response of the subject. The compounds of the present disclosure are generally effective over a wide dosage range. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject.
[0057] In certain embodiments, pharmaceutical compositions may comprise, for example, at least about 0.1% of an active compound. In other embodiments, an active compound may comprise between about 2% to about 75% of the weight of the unit, or between about 25% to about 60%, for example, and any range derivable therein. Naturally, the amount of active compound(s) in each therapeutically useful composition may be prepared in such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by those preparing such
pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.
[0058] In other non-limiting examples, a dose may also comprise from about 1
microgram kg/body weight, about 5 micro gram/kg/body weight, about 10 microgram kg/body weight, about 50 microgram kg/body weight, about 100 microgram/kg/body weight, about 200 microgram/kg/body weight, about 350 microgram/kg/body weight, about 500 microgram/kg/body weight, about 1 milligram/kg/body weight, about 5 milligram/kg/body weight, about 10 milligram/kg/body weight, about 50 milligram/kg/body weight, about 100 milligram/kg/body weight, about 200 milligram/kg/body weight, about 350 milligram/kg/body weight, about 500 milligram/kg/body weight, to about 1000 mg/kg/body weight or more per administration, and any range derivable therein. In non-limiting examples of a derivable range from the numbers listed herein, a range of about 5 mg/kg/body weight to about 100 mg/kg/body weight, about 5 microgram/kg/body weight to about 500 milligram/kg/body weight, etc., can be administered, based on the numbers described above. The dosages will depend on many factors, and will in any event be determined by a suitable practitioner. Therefore, the dosages described herein are not intended to be limiting.
[0059] In some embodiments, the compositions further include an additional active ingredient, in addition to the thrombolytic drug and metal ion chelator. The preparation of a pharmaceutical
composition that contains at least one compound or additional active ingredient will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington' s
Pharmaceutical Sciences, 2003, incorporated herein by reference. Moreover, for animal (e.g., human) administration, it will be understood that preparations should meet sterility, pyrogenicity, and general safety and purity standards as required by the FDA Office of Biological Standards. In certain embodiments, pharmaceutical compositions of the present disclosure comprise an effective amount of a thrombolytic drug and an effective amount of a metal ion chelator, and/or additional agents, dissolved or dispersed in a pharmaceutically acceptable carrier. Suitable additional agents include, but are not limited to, anti-coagulants or blood thinners. In some non-limiting examples, the composition includes an additional agent selected from the group consisting of: aspirin, heparin, coumarins (such as warfarin), clopidogrel, oxalate, citrate, hirudin, and combinations thereof.
[0060] KITS
[0061] The compositions and methods described herein can be embodied as parts of a kit or kits. A non-limiting example of such a kit comprises the ingredients for preparing a composition, namely a thrombolytic drug and a metal ion chelator, in separate (or at least two or more) containers, where the containers may or may not be present in a combined configuration. Many other kits are possible, such as kits comprising a second metal ion chelator or pharmaceutically acceptable additive in a separate container. In certain embodiments, the kits further comprise a means for administering the composition, such as a syringe. The kits may further include instructions for using the components of the kit to practice the subject methods. The instructions for practicing the subject methods are generally recorded on a suitable recording medium. For example, the instructions may be present in the kits as a package insert or in the labeling of the container of the kit or components thereof. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, such as a flash drive, CD-ROM, or diskette. In other embodiments, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, such as via the internet, are provided. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.
[0062] EXAMPLES
[0063] Example 1 - tPA
[0064] An in vitro clot model and an animal model were used to evaluate the effects of Zn and Fe on tPA-induced thrombolysis, as well as the effects of co-applying a metal ion chelator with the tPA. The results show that zinc and iron inhibit thrombolysis by reducing the efficacy of tPA. Chelating extracellular free zinc and iron by EDTA increased tPA efficacy and promoted tPA- induced thrombolysis in vitro. Furthermore, in vivo application of CaEDTA increased the efficacy
and potency of tPA.
[0065] Recombinant tPA (Genentech, South San Fransisco, CA) was used for the tests in this example. The thrombus in vitro was made of recalcified mice whole blood at 37 °C for 3h incubation. Thrombolysis was quantified by spectrophotometry at 580 nm wavelength.
Alteplase/Activase (tPA) was used for thrombolysis. Zn2+, Ca2+, Fe3+, and Fe2+ were added together with tPA accordingly. EDTA was used for ion chelation. In vivo, Rose Bengal (4,5,6,7- tetrachloro-2*,4',5',7'-tetraiodofluorescein) and local light exposure were used to introduce photo- thrombosis at the femoral artery. Thrombolysis was monitored and quantified by microscopy with software. The results show that Zn2+, Fe3+, and Fe2+ inhibited thrombolysis of tPA, with Zn2+ and Fe2+ being the most potent. Ion chelation of EDTA markedly increased the efficacy of thrombolysis. Data in vivo show that adding calcium saturated EDTA (CaEDTA) improved the thrombolysis rate to 66.7% compared with 20% in tPA alone. Analysis of the thrombolysis images show that EDTA accelerated thrombolysis compared with that of tPA alone. These result indicate that zinc and iron inhibit the tPA reaction. Chelation of zinc and iron improves efficacy and potency of tPA in thrombolysis.
[0066] Citrated blood of male CD1 mice was purchased from Innovative research (46430 Peary Court Novi, MI 48377) and BioChemed services (172 Linden Drive, SuitelOl, Winchester, VA 22601). Blood arrived on the next day of harvest and was stored in 4 °C. Citrated blood was used in 3 days due to its decreased clotting ability. An aliquot of 200 μΐ blood was placed in 0.5 ml tubes and recalcified with 3 μΐ of 1M CaC . The blood samples were incubated in 0.5 ml centrifuge tubes at 37 °C for 3 hours. Blood clots were gently rinsed by saline 3 times and then transferred to custom-modified cuvettes for measurement of absorbance.
[0067] Custom-modified cuvettes were designed for the absorbance measurement. A schematic diagram of these modified cuvettes is shown in FIG. 3A. A nylon web was placed at the narrowed part of the cuvette to separate the cuvette into an upper chamber and a lower chamber. The lower chamber was where the light passed through during spectrophotometric measurement. The optical intensity change of the light was detected and shown as absorbance value. The upper chamber was to hold the blood clot from interfering with the measurement. Cuvettes were filled with tPA in 1.5 ml saline solution. The lysis treatments were tPA, tPA plus EDTA, and tPA plus metal ions (Zn2+, Ca2+, Fe3+, or Fe2+). At the start of blood clot- lysis, the color of lysate was clear and the absorbance (optical density) was low. As the blood clots were being lysed, more hemoglobin was released into the vehicle, which gave samples a red color and increased absorbance (FIGS. 3A- 3B).
[0068] A spectrophotometer (Biomate3) from Thermo Spectronic (Waltham, MA, USA) was used to test the most sensitive wavelength for hemoglobin at 500 nm to 600 nm. The peaks of absorbance were between 540 nm and 580 nm, which was consistent with previous hemoglobin studies. The wavelength of 580 nm was chosen to measure the absorbance as the optimal
wavelength. Samples (cuvettes with blood clots and lysis treatments dissolved in saline) were placed in the spectrophotometer. Saline was used to set up the absorbance baseline. The absorbance of each sample was measured every 5 minutes, for up to 1 hour. The absorbance change between two time points divided by the time duration was considered the rate of lysis.
[0069] Adult CD1 mice (male) were kept under 12-h light/12-h dark cycles and acclimatized for at least 24 h before surgery. All animal work in this example was conducted according to Ohio University Institutional Animal Care and Use Committee (IACUC) guidelines.
[0070] The CD1 mouse was anesthetized by intraperitoneal (IP) injection with a cocktail of ketamine, xylazine, and aceptromazine. The anesthesia cocktail was made by Ketamine (100 mg/ml) 1 ml, Xylazine (20 mg/ml) 1 ml, Aceptromazine (10 mg/ml) 0.3 ml, and sterile water or saline 7.7 ml. According to the body weight, 6.5 μΐ/g anesthesia cocktail was given through IP injection. The mouse (in surgical plane anesthesia) was placed on dorsal recumbency on a heat plate connected with ATC 1000 animal temperature controller (World Precision Instruments, 175 Sarasota Center Boulevard, Sarasota, FL 34240-9258 USA). The femoral artery of the mouse was exposed, followed by the intravenous injection of Rose Bengal (30 mg kg). Cold white light that was provided by a Fiber-Lite Illuminator through a probe in 2.16 mm diameter (Dolan-Janner Industries) was placed on the femoral artery. The light intensity was 1300 μW/cm2. The duration of light exposure was 20 minutes. Occlusion of the femoral artery was observed at the location of light exposure, as a dark blood clot and emptiness observed downstream. 2 mg/kg tPA was given to the mouse with 0.01 mg as initial bolus, then 30-minute perfusion of the rest via Syringe Infusion Pump 22 (Harvard Apparatus, Holliston, MA). Half dose of tPA was lmg/kg, with 0.01 mg as initial bolus and 30-minute perfusion of the rest.
[0071] Images of the femoral arteries were taken under dissection microscope connected with a Moticam 2500 camera and Motic Images Plus 2.0 software. Images from each trial were made into sequenced images and analyzed by ImagePro software to quantify the thrombolysis process. The rest of the images were taken by a Nikon 300s.
[0072] Ethylenedinitrilo-tetraacetic acid (EDTA) was purchased from Eastman (Kingsport, Tennessee). Rose Bengal and Ethylenediaminetetraacetic acid disodium-calcium salt (CaEDTA) were purchased from Sigma Aldrich (St Louis, MO). Alteplase/Activase (tPA) was purchased from Genentech (South San Francisco, CA). All chemicals were dissolved in saline unless stated otherwise.
[0073] Statistical analysis of the percentage of reperfusion under different treatment of lysis was performed using Fisher's exact test under R program. Statistical analysis of absorbance increase of clot lysis and the rate change were performed using two-tailed Student t test under Microsoft Excel. P < 0.05 was considered significant.
[0074] The amount of hemoglobin in a solution can be measured by a spectrophotometer and shown as absorbance. The more hemoglobin contained in a sample, the more opaque the sample
becomes. Therefore, a sample yields increasing absorbance value when hemoglobin keeps being released. In this example, the blood clot lysis (thrombolysis) was monitored and quantified by measuring the absorbance change at 580 nm wavelength. The amplitudes of absorbance were depicted in arbitrary units.
[0075] When the blood clots were first transferred into cuvettes, the samples were clear with low absorbance value (FIG. 3B). As tPA was lysing the clots, hemoglobin was released into clear solution, which gives the sample an increased absorbance value (FIG. 3C). Additionally, different doses of tPA (from 0.005 mg to 0.05 mg, as shown in FIG. 3C, cuvettes 1-3) resulted in different amounts of hemoglobin release. Therefore, the higher absorbance value indicated a greater amount of thrombolysis. A steady increase of absorbance value started 10 minutes after the initiation of thrombolysis, and the absorbance value kept increasing within the one-hour observation (FIG. 4A). The thrombolysis of vehicle (saline) was also measured. The vehicle showed an extremely low level of thrombolysis (FIG. 4B). The measurement of absorbance was performed every 5 minutes. The absorbance change per minute was calculated as the velocity of the thrombolysis reaction. The amplitudes of rate were depicted in arbitrary units. The rate of thrombolysis started to increase after 10 minutes and reached the maximum at 20-25 minutes (FIG. 4C).
[0076] To investigate the effect of metal ions on thrombolysis, Zn2+, Ca2+, Fe2+, and Fe3+ were added accordingly together with tPA during thrombolysis. Spectrophoto metric measurement showed a decrease of overall absorbance in Zn2+, Fe2+, and Fe3+ treated groups, indicating that Zn2+, Fe2+, and Fe3+ attenuated thrombolysis of tPA. Both Zn2+ and Fe2+ yielded potent inhibition in overall thrombolysis and decreased the efficacy (maximum rate) of thrombolysis. Compared to the two divalent cations, the inhibiton caused by Fe3+ is much milder (FIGS. 4B, 4D). Fe3+ is not as stable as Fe2+. Without wishing to be bound by theory, it is believed this is why Fe2+ was seen to be more effective at inhibition of thrombolysis than Fe3+ was. Ca2+ did not affect thrombolysis of tPA.
[0077] The effect of each ion (Zn2+, Fe2+, Fe3+) was further tested in different doses. At low dose (10 μΜ), only Zn2+ yielded mild inhibition in thrombolysis. Fe2+ did not affect tPA, and Fe3+ slightly increased thrombolysis (FIGS. 5A, 5D, 5G). At medium dose (100 μΜ), all three ions steadily inhibited thrombolysis throughout the one-hour observation. At high concentration (200 μΜ), Zn2+ and Fe2+ markedly decreased thrombolysis. Fe2+ yielded significant inhibition from 30 minutes to 55 minutes of thrombolysis. Zn2+ inhibited thrombolysis from 10 minutes onward. Of the three ions, Zn2+ inhibited thrombolysis most consistently in a dose-dependent manner. The inhibition effect of Fe2+ is significant and saturated at 100 μΜ, with no further inhibition at 200 μΜ. Fe3+ yielded mild but significant inhibition only at 100 μΜ (FIGS. 5A-5I).
[0078] The rate of tPA reaction gradually went up and reached the maximum at 20-25 minutes (FIG. 2B, FIGS. 6A-6I). Zn2+ started to show significant inhibition effect at 10 μΜ, during the
first 30 minutes of thrombolysis, but slightly increased the rate after 40 minutes of the reaction. In a dose-dependent manner, the inhibition effect of Zn2+ lasted longer through the thrombolysis as the Zn2+ concentration increased (FIGS. 6D-6F). Fe2+ did not affect the reaction rate at 10 μΜ (FIG. 6G). The inhibition of Fe2+ on the reaction rate was significant and saturated at 100 μΜ. Increasing Fe2+ concentration over 100 μΜ did not enhance the inhibition. Fe3+ showed a slight effect of promotion on tPA, and only showed consistent inhibition at ΙΟΟμΜ. These results indicate that Zn2+ acts as a reliable inhibitor in thrombolysis, by reducing the rate of the tPA reaction. Locally high dose (100 μΜ-200 μΜ) of Fe3+ and Fe2+ as well contributed to reducing tPA-induced thrombolysis (FIGS. 6A-6I).
[0079] EDTA was used as a reliable and high-affinity zinc and iron chelator. Blood clots were assigned into two groups. One group was treated with tPA alone. The other group was treated with EDTA (5 mM) together with tPA. The EDTA group significantly augmented the amount of thrombolysis from 20 minutes of the reaction (FIG. 7A).
[0080] In the trend of reaction rate, the treatment of (tPA + EDTA) started to separate itself as being significant higher than tPA-only treatment at 15 minutes (FIG. 7B). Both treatments had a similar trend of speed change, with higher amplitude in (tPA + EDTA) group. However, with EDTA treatment, the maximum speed of thrombolysis was dramatically higher when EDTA was co-treated with tPA. EDTA yielded a significant higher velocity of thrombolysis from 15 minutes to 40 minutes. After 40 minutes, the curves of reaction rate in EDTA group and tPA alone group merged together.
[0081] Photothrombosis is to introduce in vivo blood clotting by light exposure. Rose Bengal is a photosensitive chemical producing singlet oxygen under light exposure. Singlet oxygen breaks down endothelial cells of the blood vessel and initiates thrombosis. The femoral artery runs superficially in the hind limb of mice (FIG. 8A). The occlusion of the femoral artery was achieved by a photothrombotic method. Rose Bengal was systematically delivered through the tail vein followed by 20 minutes of light exposure (intensity: 1300
on top of the femoral artery. The successful occlusion was shown after light exposure as a dark blood clot in exposed location and emptiness of the artery downstream (FIG. 8B).
[0082] The dose of tPA was given by body weight through 30 minutes of continuous intravenous perfusion which was preceded by a tPA bolus. Images of the femoral artery were acquired every 10 minutes under a dissection microscope. The blood clot in the femoral artery was initially dark, and gradually became lighter during the tPA treatment. The reperfusion was observed as blood refilling in the previous empty downstream region in the femoral artery (FIG. 8C), which was later confirmed by cutting the artery downstream of the occlusion. Bleeding was considered as successful reperfusion of the artery. In some cases, reperfusion was not achieved. Unsuccessful reperfusion was shown as a dark blood clot still occluding the vessel with emptiness remained in the artery (FIG. 8B) and no bleeding when the femoral artery was cut open.
[0083] ImagePro was used to quantify the sequenced images of each trial. Change of light transmission in the blood clot was measured as light intensity change, which was shown as (F- Fo)/Fo in arbitrary units. In the reperfused cases, light transmission of the blood clot was gradually increased which was shown as a positive change of light transmission. In non-reperfused cases, in contrast, light transmission was decreased, which caused change of light transmission being negative. The two groups had less than 1 % overlap at all time points, so the positive change of light transmission was used as an indicator of successful thrombolysis (FIG. 9B).
[0084] EDTA, the high affinity chelator of zinc and iron, also combines with calcium. Given the fact that plasma contains high level of calcium, in order to maintain calcium homeostasis in blood, calcium saturated EDTA (CaEDTA) was used in in vivo experiments instead of EDTA to minimize calcium disturbance. CaEDTA was applied so that normal calcium concentration was maintained. Calcium is known to play an important role in physiological functions and is an important factor contributing to coagulation.
[0085] After photothrombotic treatment, thrombolysis agents were given through intravenous perfusion. Three different treatments, which were tPA (20 mg kg), half dose of tPA (10 mg kg), and half dose of tPA plus CaEDTA (30 mg/kg), were given accordingly. Images of the occluded femoral artery were taken every 10 minutes since the intravenous perfusion started.
Representative images of each treatment were shown in FIG. 8. In the tPA (20 mg/kg) group, most of the occlusion cases (7/10) were successfully perfused, accounting for 70%. This reperfusion percentage was decreased to 20% when the dose of tPA was reduced into half (10 mg/kg). However, the poor reperfusion outcome was significantly improved in the presence of CaEDTA. Half dose of tPA combined with CaEDTA yielded 66.7% perfused rate (Table 1, FIG. 10A). The results indicate that ion chelation improves the potency of tPA-induced thrombolysis, and with the help of chelation, the necessary dose of tPA can be reduced.
[0086] ImagePro was used to analyze the speed of thrombolysis of tPA treatment and half dose of tPA (½tPA) co-administrated with CaEDTA, which is indicated as the change of light transmission. Although two treatments yielded a similar rate of reperfusion (FIG. 10A, Table 1), ½ tPA together with CaEDTA showed faster thrombolysis during the first 20 minutes (FIG. 11). The data revealed that ion chelation not only improved thrombolysis outcomes of tPA, but also accelerated the thrombolysis process.
[0087] This example demonstrates that zinc and iron inhibit tPA-induced thrombolysis by reducing the overall effectiveness of tPA. The kinetics of thrombolysis was quantified by using spectrophotometry in vitro. The removal of zinc and iron with metal ion chelation increased tPA efficacy and promoted tPA-induced thrombolysis of the femoral artery thrombus in vivo.
Application of the chelator alone did not cause a noticeable clot lysis. The co- application of metal ion chelator CaEDTA and tPA showed significant increases in the rate and the amplitude of thrombolysis. In other words, significantly higher thrombolysis was achieved by the co-
application of the metal ion chelator and tPA than that by tPA alone, and this higher thrombolysis was even higher than that achieved by double the amount of tPA alone. Importantly, these results indicate that the application of metal ion chelator, removing zinc and iron, enhances overall tPA- induced thrombolysis. Furthermore, this regiment can improve the safety of tPA by reducing the tPA dose.
[0088] This example further demonstrates that the application of zinc significantly inhibits tPA- induced thrombolysis by reducing tPA' s potency and efficacy (maximum rate of thrombolysis) of the reaction in a dose-dependent manner. Zn2+ started to show inhibition at 10 μΜ. When Zn2+ concentration was as high as 100 μΜ or 200 μΜ, the amount of thrombolysis was significantly reduced (FIGS. 5E-5F, 6E-6F). Application of zinc itself (without tPA) did not have an effect on the blood clot. This indicates that there is direct interaction between zinc and tPA. Without wishing to be bound by theory, it is believed that zinc binds to tPA and suppresses the conversion of plasminogen to plasmin in a dose-dependent manner. However, the sites of the zinc binding domain in tPA remain unknown.
[0089] The tests in the lysis of the whole blood clot, which is a more physiologically and pathophysiologically relevant model, indicate further the direct inhibitory action of zinc on tPA. Zinc also acts on others: zinc binds heparin and neutralizes its effect of anticoagulation, and zinc abolishes the enhancement effect of decorin on tPA. Because zinc inhibits tPA lysis, the chelation of zinc enhances its effect. The metal ion chelator not only removes cirlulation zinc but also zinc dissociated from thrombi where tPA directly interact in thrombus. Removal of zinc or iron with metal ion chelation facilitates tPA mediated thrombolysis by removing the inhibitory effect of zinc or iron. The aggregation and accumulation of platelets produce a high concentration of zinc in the clot.
[0090] Erythrocytes contain 2-3 g iron, or about 2/3 of the total iron contained in the body, with hemoglobin as one of the major sites of storage. Iron is an important factor in blood coagulation. The erythrocyte is another major composite in the clot. During thrombolysis, the release of hemoglobin contributes to locally high concentration of Fe3+ and Fe2+. In this example, Fe3+ was observed to postpone the maximum velocity of thrombolysis at 100 μΜ dose (FIG. 6B). At 200 μΜ, Fe3+ significantly reduced the efficacy of tPA-induced thrombolysis (FIG. 6C). Fe2+ showed more severe inhibition by reducing velocity of the thrombolysis reaction than Fe3+ at 100 μΜ and 200 μΜ (FIGS. 6H, 61). Without wishing to be bound by theory, it is believed that when iron is binding to proteins, the bond distance generated by trivalent iron (Fe3+) is longer than that generated by divalent iron (Fe2+). Therefore, Fe2+ binding with proteins is more stable.
[0091] Increased circulating ferritin and free iron have been found in a variety of disease states associated with thrombophilia. When blood or plasma is exposed to iron addition, characteristic changes in thrombus formation are observed by scanning electron microscopy, which include fusion of fibrin polymers, matting, and even sheeting of fibrin. Fe3+ generates hydroxyl radicals
by the following reaction: Fe3+ + HCT→ Fe2+ + HO. Whole blood studies have revealed that fibrinogen can be converted to a fibrin-like polymer in the presence of hydro xyl radicals. Fe3+ also strengthens fibrin and makes it more resistant to proteolysis. Without wishing to be bound by theory, it is believed that the mechanism of Fe2+ is that iron blocks the fibrinolysis pathway by either binding and inhibiting tPA like zinc, or by blocking the pathway of fibrin degradation. The in vitro results of this example showed no effect of inhibition on thrombolysis when adding 10 μΜ of Fe3+ or Fe2+ (FIGS. 5A, 5G). The explanation is that increase of iron may promote plasmin activity on the cell surface. When increasing iron concentration, the inhibition effect of iron overcomes the promotion effect by suppressing fibrinolytic enzymes and accelerating thrombosis. Thus, reversible iron binding to fibrinogen mechanistically explains a significant portion of coagulation kinetic and ultrastructural hypercoagulability.
[0092] As seen in this example, CaEDTA promotes thrombolysis by augmenting efficacy of tPA-mediated thrombolysis. The efficacy of thrombosis, which is represented by the maximum velocity, is increased by 55% by EDTA (FIG. 7B). Among Zn2+, Fe2+ and Fe3+, the enhancement of thrombolysis by EDTA is because of Zn2+ and Fe3+chelation, not Fe3+, drop. This is because the application of Fe3+ has little effect on tPA-induced thrombolysis. Interestingly, even though Fe3+ has a much higher binding affinity to EDTA than Zn2+, Zn2+ is able to displace Fe3+-EDTA. Without wishing to be bound by theory, it is believed that Zn2+ reduces FeEDTA-mediated oxidation by 90% when Zn2+ is added in 1 : 1 molar ratio to Fe3+. The mechanism of displacement of Fe3+ from EDTA by Zn2+ is not settled. It may involve hydrolysis-aided dissociation of Fe3+, or the reduction of Fe3+ (as a redox-active ion) to Fe2+ which is outcompeted by Zn2+ at binding EDTA.
[0093] As seen from FIGS. 9A-9B, ion chelation improves reperfusion outcomes in vivo after photothrombosis of the artery. FIG. 9A shows representative sequenced images of tPA-induced thrombolysis in the femoral artery (outlined by dash lines). (Scale bar: 0.5 mm.) FIG. 9B shows sequenced images of thrombolysis analyzed by ImagePro and presented as the change of light transmission every 5 minutes during tPA perfusion. Reperfused cases generate a positive change in light transmission, indicating the blood clot being lysed gradually. Thrombosis from non- perfused cases generate a negative change of light transmission due to unsuccessful lysis. The two groups have less than 1% overlap (p < 0.01).
[0094] A significant superior effect of thrombolysis can be seen when chelation is combined with tPA, as compared to tPA being used alone (FIGS. 9A-9B). A half dose of tPA plus CaEDTA achieved a similar reperfusion rate to a full dose of tPA alone (Table 1, FIG. 10A), demonstrating that CaEDTA increases the potency of tP A- mediated thrombolysis. The measurement of light transmission of the thrombosis showed that the half dose of tPA together with CaEDTA lysed the blood clot faster than the full dose of tPA (FIG. 11). Thus, metal ion chelators such as EDTA increase the efficacy of thrombolysis in vitro. The data indicates that by co-applying CaEDTA
with tPA, the therapeutic dose of tPA is reduced with improved efficacy. This combination can therefore lead to fewer side effects and better thrombolytic outcomes. Reducing the tPA dose (from 1 mg kg to 0.5 mg kg) has been shown to shorten the primary bleeding time by 60%.
Secondly, the application of tPA during stroke increases the permeability of the blood-brain barrier, thereby causing brain edema. tPA induces brain edema without plasminogen or matrix metallopeptidases,and tPA-deficient mice have reduced edema size. Additionally, the cytotoxicity of tPA contributes to neuronal death. Therefore, by reducing the therapeutic dose of tPA, co- application of ion chelation can reduce side effects of thrombolysis, and can extend the window of its clinical application.
[0095] Example 2 - Streptokinase
[0096] The effect of metal ion chelators on streptokinase-induced thrombolysis was investigated using procedures similar to those described in Example 1. The co- application of a metal ion chelator, CaEDTA or TPEN, with the thrombolytic drug streptokinase also increased clot lysis when compared to lysis of the control groups streptokinase, CaEDTA, or TPEN alone (FIG. 12). As seen from FIG. 12, the addition of a metal ion chelator without streptokinase showed little to no lysis. As seen from FIG. 13, the addition of zinc (200 μΜ) inhibited the streptokinase (SK)- induced clot lysis when compared to the lysis of the streptokinase treatment group.
[0097] Certain embodiments of the compositions and methods disclosed herein are defined in the above examples. It should be understood that these examples, while indicating particular embodiments of the invention, are given by way of illustration only. From the above discussion and these examples, one skilled in the art can ascertain the essential characteristics of this disclosure, and without departing from the spirit and scope thereof, can make various changes and modifications to adapt the compositions and methods described herein to various usages and conditions. Various changes may be made and equivalents may be substituted for elements thereof without departing from the essential scope of the disclosure. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the disclosure without departing from the essential scope thereof.
Claims
1. A composition comprising:
an effective amount of a thrombolytic drug;
at least one metal ion chelator capable of chelating zinc or iron; and
a pharmaceutically acceptable excipient, diluent, or carrier.
2. The composition of claim 1, wherein the thrombolytic drug comprises tissue plasminogen activator (tPA).
3. The composition of claim 1, wherein the thrombolytic drug comprises streptokinase.
4. The composition of claim 1, wherein the metal ion chelator is capable of chelating both zinc and iron.
5. The composition of claim 1, wherein the metal ion chelator comprises ethylenediaminetetra-acetic acid (EDTA).
6. The composition of claim 5, wherein the EDTA comprises calcium saturated EDTA (CaEDTA).
7. The composition of claim 1, wherein the effective amount of the thrombolytic drug is less than an amount of the thrombolytic drug needed to be effective in the absence of the at least one metal ion chelator.
8. The composition of claim 1, wherein the effective amount of the thrombolytic drug ranges from about 0.25 mg/kg to about 20 mg kg.
9. The composition of claim 1, wherein the effective amount of the thrombolytic drug is about 2 mg kg.
10. The composition of claim 1, wherein the effective amount of the thrombolytic drug is about 1 mg/kg.
11. The composition of claim 1, wherein the effective amount of the thrombolytic drug is about 0.5 mg kg.
12. The composition of claim 1, wherein the metal ion chelator is present at a concentration ranging from about 1 μΜ to about 100 mM.
13. The composition of claim 1, further comprising a second metal ion chelator capable of chelating zinc or iron.
14. The composition of claim 1, wherein the metal ion chelator comprises Ν,Ν,Ν',Ν'- tetrakis(2-pyrdiylmethyl) ethylenediamine (TPEN).
15. The composition of claim 1, wherein the metal ion chelator comprises EDTA and
TPEN.
16. The composition of claim 1, further including an additional agent selected from the group consisting of: aspirin, heparin, coumarins (such as warfarin), clopidogrel, oxalate, citrate, hirudin, and combinations thereof.
17. A method of treating a clotting event, the method comprising:
administering an effective amount of a metal ion chelator to a patient having a clotting event; and
administering an effective amount of a thrombolytic drug to the patient to treat the clotting event.
18. The method of claim 17, wherein the thrombolytic drug comprises tissue plasminogen activator (tPA).
19. The method of claim 17, where the metal ion chelator and the thrombolytic drug are administered simultaneously.
20. The method of claim 19, wherein the metal ion chelator and the thrombolytic drug are in a single composition.
21. The method of claim 17, wherein the metal ion chelator and the thrombolytic drug are administered sequentially.
22. The method of claim 17, wherein the clotting event is selected from the group consisting of: stroke, myocardial infarction, vein thrombosis, and pulmonary embolism.
23. The method of claim 17, wherein the clotting event is a stroke, and the thrombolytic drug is tPA.
24. The method of claim 23, wherein the effective amount of the tPA is about 0.5 mg/kg or higher.
25. The method of claim 17, wherein the metal ion chelator comprises EDTA.
26. The method of claim 25, wherein the metal ion chelator comprises calcium saturated EDTA (CaEDTA).
27. The method of claim 17, wherein the metal ion chelator comprises TPEN.
28. The method of claim 17, wherein the thrombolytic drug comprises streptokinase.
29. The method of claim 28, wherein the effective amount of streptokinase ranges from about 10,000 units to about 100,000,000 units.
30. The method of claim 17, wherein the metal ion chelator comprises EDTA and
TPEN.
31. A kit for preparing a composition, the kit comprising:
a first container housing a thrombolytic drug; and
a second container housing a metal ion chelator.
32. The kit of claim 31, wherein the metal ion chelator comprises EDTA and the thrombolytic drug comprises tPA.
The kit of claim 31, further comprising a syringe
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562157808P | 2015-05-06 | 2015-05-06 | |
US62/157,808 | 2015-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016179217A1 true WO2016179217A1 (en) | 2016-11-10 |
Family
ID=57217863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/030663 WO2016179217A1 (en) | 2015-05-06 | 2016-05-04 | Metal ion chelation for enhancing the effect of tissue plasminogen activator (tpa) in thromobolysis |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016179217A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997009976A2 (en) * | 1995-09-01 | 1997-03-20 | Washington University | Method of reducing neurotoxic injury with zinc chelators |
US6087332A (en) * | 1997-12-23 | 2000-07-11 | Galler; Lawrence Isaac | Streptokinase derivatives with high affinity for activated platelets and methods of their production and use in thrombolytic therapy |
WO2008051599A2 (en) * | 2006-10-27 | 2008-05-02 | Medivation Neurology, Inc. | Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil |
WO2011060789A2 (en) * | 2009-11-18 | 2011-05-26 | H. Lundbeck A/S | Treatment of acute ischemic stroke or intracranial bleeding with tpa and carbamylated erythropoietin |
US20140179741A1 (en) * | 2012-10-10 | 2014-06-26 | Massachusetts Institute Of Technology | Use of chelators of divalent cations to promote nerve regeneration |
-
2016
- 2016-05-04 WO PCT/US2016/030663 patent/WO2016179217A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997009976A2 (en) * | 1995-09-01 | 1997-03-20 | Washington University | Method of reducing neurotoxic injury with zinc chelators |
US6087332A (en) * | 1997-12-23 | 2000-07-11 | Galler; Lawrence Isaac | Streptokinase derivatives with high affinity for activated platelets and methods of their production and use in thrombolytic therapy |
WO2008051599A2 (en) * | 2006-10-27 | 2008-05-02 | Medivation Neurology, Inc. | Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil |
WO2011060789A2 (en) * | 2009-11-18 | 2011-05-26 | H. Lundbeck A/S | Treatment of acute ischemic stroke or intracranial bleeding with tpa and carbamylated erythropoietin |
US20140179741A1 (en) * | 2012-10-10 | 2014-06-26 | Massachusetts Institute Of Technology | Use of chelators of divalent cations to promote nerve regeneration |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004255268B2 (en) | Use of nitrite salts for the treatment of cardiovascular conditions | |
AU2006282030B2 (en) | Acetylcysteine composition and uses therefor | |
Calcerrada et al. | Nitric oxide-derived oxidants with a focus on peroxynitrite: molecular targets, cellular responses and therapeutic implications | |
US8722738B2 (en) | Acetycysteine compositions and methods of use thereof | |
US20090011051A1 (en) | Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds | |
US4937070A (en) | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids | |
MXPA06014096A (en) | Stabilized compositions comprising a therapeutically active agent, citric acid or a conjugated base and chlorine dioxide. | |
Hess et al. | Free radicals, calcium homeostasis, heat shock proteins, and myocardial stunning | |
EP3419683A1 (en) | Nitric oxide generating formulations and kits | |
KR20020060080A (en) | Stabilized liquid preparation of the protease which activates blood coagulation factor VII, or of its proenzyme | |
WO2016179217A1 (en) | Metal ion chelation for enhancing the effect of tissue plasminogen activator (tpa) in thromobolysis | |
US6235279B1 (en) | Method for treating thromboembolic conditions by inhibiting reocclusion via the use of multiple bolus administration of thrombolytically active proteins | |
AU2006270094A1 (en) | Prevention and treatment of ophthalmic complications of diabetes | |
US9918964B2 (en) | Reducing platelet activation, aggregation and platelet-stimulated thrombosis or blood coagulation by reducing mitochondrial respiration | |
Ha et al. | Mechanism of ischemia and reperfusion injury to the heart: from the viewpoint of nitric oxide and mitochondria | |
WO2005079782A1 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of endothelial dysfunction | |
JP2017533961A (en) | Methods and compositions for safe and effective thrombolysis | |
CA3231958A1 (en) | Engineered antimicrobial peptides and usage thereof | |
JP2004526792A (en) | Use of mangafodipir to treat oxidative invasive effects | |
US20220354930A1 (en) | Hemoglobin Substitute Mixtures Including Reconstituted Plasma and Platelets and Their Manufacture and Use | |
WO2022177897A1 (en) | Methods of treating a subject exposed to a toxic inhaled chemical with mesna | |
CA3205756A1 (en) | Fixed dosage antibiotic compositions | |
JP2005529140A (en) | Complex product comprising anticoagulant and antiarrhythmic oxabispidine | |
WO2018089248A2 (en) | E-we thrombin analog and fibrinolytic combination | |
Machado | Minocycline vascular protection after acute ischemic stroke |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16789970 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16789970 Country of ref document: EP Kind code of ref document: A1 |